Cysteinyl leukotrienes (CysLTs) are potent pro-inflammatory mediators that are increased in samples from patients with inflammatory bowel diseases (IBDs). Individuals with IBDs have enhanced susceptibility to colon carcinogenesis. In colorectal cancer, the balance between the pro-mitogenic cysteinyl leukotriene 1 receptor (CysLT1R) and the differentiation-promoting cysteinyl leukotriene 2 receptor (CysLT2R) is lost. Further, our previous data indicate that patients with high CysLT1R and low CysLT2R expression have a poor prognosis. In this study, we examined whether the balance between CysLT1R and CysLT2R could be restored by treatment with the cancer chemopreventive agent all-trans retinoic acid (ATRA).
Promoter Methylation Of Genes In And Around The 03君瑋 徐
Genetic, epigenetic, and computational screening approaches were used to identify 43 genes located in the 6q12-27 region for characterization of methylation status in lung cancer. Twelve genes showed methylation in lung cancer cell lines, with five genes (TCF21, SYNE1, AKAP12, IL20RA, and ACAT2) exhibiting the highest prevalence of methylation. These five genes showed similar methylation patterns in lung adenocarcinoma tumors regardless of smoking status, but their methylation was not associated with patient survival.
Variant G6PD levels promote tumor cell proliferation or apoptosis via the STA...Enrique Moreno Gonzalez
Glucose-6-phosphate dehydrogenase (G6PD), elevated in tumor cells, catalyzes the first reaction in the pentose-phosphate pathway. The regulation mechanism of G6PD and pathological change in human melanoma growth remains unknown.
Targeting PIM kinase to overcome drug resistance in NSCLC - Dr Kathy GatelyHannahMcCarthy31
Dr Kathy Gately is a Clinical Scientist at St James's Hospital and Clinical Senior Lecturer at Trinity College Dublin. Dr Gately's research interests are Drug Resistance Mechanisms in Non-Small Cell Lung Cancer, Liquid Biopsy and Organoid models.
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...Mark Lipstein
This document summarizes a study examining the combination of a novel PI3Kδ inhibitor, TGR-1202, with the proteasome inhibitor carfilzomib for treating hematological malignancies. The study found that TGR-1202 synergizes strongly with carfilzomib in lymphoma, leukemia, and myeloma cell lines and primary cells by silencing c-Myc translation. This synergistic effect is driven by TGR-1202's unexpected additional activity of inhibiting CK1ε, which contributes to repressing phosphorylation of 4E-BP1 and lowering c-Myc protein levels. The results suggest that TGR-1202, as a dual PI3Kδ/CK1ε inhibitor, may have
The document describes the development of a multiplex panel to measure protein levels of HK2, PKM2, and LDHA in frozen tumor biopsies. Antibodies specific to these proteins were coupled to Luminex beads. Recombinant proteins were used to develop sandwich immunoassays and as calibrators. Sample handling procedures generated cytosolic and mitochondrial fractions from tumor tissues. The panel demonstrated proof-of-concept for monitoring PKM2 levels in cancer cell lines treated with PKM2 inhibitors in vitro.
1) The study investigated how Gram-negative bacterial lipopolysaccharide (LPS), a component of bacteria like Chlamydia and Neisseria that cause STIs, affects expression of HIV receptors in cervical epithelial cells.
2) The results showed that LPS increased expression of the CCR5 HIV co-receptor and other alternative receptors in cervical cells through activation of EGFR, ERK1/2, and COX-2 signaling pathways.
3) This suggests that STIs have the potential to enhance susceptibility to HIV infection in women by regulating expression of HIV receptors in cervical epithelial cells through an inflammatory response.
3 Regulation Of Cxcr4 Signaling By Najmaldin Saki (2)najmaldin saki
1. CXCR4 is a chemokine receptor that binds to its ligand SDF1. It plays roles in HIV infection, cancer metastasis, hematopoiesis, and organogenesis.
2. CXCR4 expression and signaling is regulated by transcription factors, cytokines, growth factors, and G protein coupling. Dysregulation of CXCR4 contributes to diseases like WHIM syndrome and various cancers.
3. In cancer, CXCR4 upregulation enhances migration and adhesion, possibly facilitating metastasis. CXCR4 expression provides survival advantages for some cancer cells through interactions with the tumor microenvironment.
HDAC4 and HDAC7 Promote Breast and Ovarian Cancer Cell Migration by Regulatin...CrimsonpublishersCancer
Breast and ovarian cancer have been remained as a highly malignant tumor among women, posing a serious threat to women health worldwide. In this study, we were aimed to investigate the underlying mechanism of breast and ovarian cancer cell migration. Wound healing assay showed that MDA-MB-231and C13* have higher migration potential compare with MCF-7 and OV2078 cells, as well as regulated epithelial-mesenchymal transition (EMT) marker. We found that HDAC4 and HADC7 mRNA are up regulated in MDA-MB-231 and C13* cells. Moreover, target HDAC4 and HDAC7 by TSA or shRNA block MDA-MB-231and C13* migration. These results reveal a new link between HDACs and EMT in the regulation of breast and ovarian cancer migration.
Promoter Methylation Of Genes In And Around The 03君瑋 徐
Genetic, epigenetic, and computational screening approaches were used to identify 43 genes located in the 6q12-27 region for characterization of methylation status in lung cancer. Twelve genes showed methylation in lung cancer cell lines, with five genes (TCF21, SYNE1, AKAP12, IL20RA, and ACAT2) exhibiting the highest prevalence of methylation. These five genes showed similar methylation patterns in lung adenocarcinoma tumors regardless of smoking status, but their methylation was not associated with patient survival.
Variant G6PD levels promote tumor cell proliferation or apoptosis via the STA...Enrique Moreno Gonzalez
Glucose-6-phosphate dehydrogenase (G6PD), elevated in tumor cells, catalyzes the first reaction in the pentose-phosphate pathway. The regulation mechanism of G6PD and pathological change in human melanoma growth remains unknown.
Targeting PIM kinase to overcome drug resistance in NSCLC - Dr Kathy GatelyHannahMcCarthy31
Dr Kathy Gately is a Clinical Scientist at St James's Hospital and Clinical Senior Lecturer at Trinity College Dublin. Dr Gately's research interests are Drug Resistance Mechanisms in Non-Small Cell Lung Cancer, Liquid Biopsy and Organoid models.
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...Mark Lipstein
This document summarizes a study examining the combination of a novel PI3Kδ inhibitor, TGR-1202, with the proteasome inhibitor carfilzomib for treating hematological malignancies. The study found that TGR-1202 synergizes strongly with carfilzomib in lymphoma, leukemia, and myeloma cell lines and primary cells by silencing c-Myc translation. This synergistic effect is driven by TGR-1202's unexpected additional activity of inhibiting CK1ε, which contributes to repressing phosphorylation of 4E-BP1 and lowering c-Myc protein levels. The results suggest that TGR-1202, as a dual PI3Kδ/CK1ε inhibitor, may have
The document describes the development of a multiplex panel to measure protein levels of HK2, PKM2, and LDHA in frozen tumor biopsies. Antibodies specific to these proteins were coupled to Luminex beads. Recombinant proteins were used to develop sandwich immunoassays and as calibrators. Sample handling procedures generated cytosolic and mitochondrial fractions from tumor tissues. The panel demonstrated proof-of-concept for monitoring PKM2 levels in cancer cell lines treated with PKM2 inhibitors in vitro.
1) The study investigated how Gram-negative bacterial lipopolysaccharide (LPS), a component of bacteria like Chlamydia and Neisseria that cause STIs, affects expression of HIV receptors in cervical epithelial cells.
2) The results showed that LPS increased expression of the CCR5 HIV co-receptor and other alternative receptors in cervical cells through activation of EGFR, ERK1/2, and COX-2 signaling pathways.
3) This suggests that STIs have the potential to enhance susceptibility to HIV infection in women by regulating expression of HIV receptors in cervical epithelial cells through an inflammatory response.
3 Regulation Of Cxcr4 Signaling By Najmaldin Saki (2)najmaldin saki
1. CXCR4 is a chemokine receptor that binds to its ligand SDF1. It plays roles in HIV infection, cancer metastasis, hematopoiesis, and organogenesis.
2. CXCR4 expression and signaling is regulated by transcription factors, cytokines, growth factors, and G protein coupling. Dysregulation of CXCR4 contributes to diseases like WHIM syndrome and various cancers.
3. In cancer, CXCR4 upregulation enhances migration and adhesion, possibly facilitating metastasis. CXCR4 expression provides survival advantages for some cancer cells through interactions with the tumor microenvironment.
HDAC4 and HDAC7 Promote Breast and Ovarian Cancer Cell Migration by Regulatin...CrimsonpublishersCancer
Breast and ovarian cancer have been remained as a highly malignant tumor among women, posing a serious threat to women health worldwide. In this study, we were aimed to investigate the underlying mechanism of breast and ovarian cancer cell migration. Wound healing assay showed that MDA-MB-231and C13* have higher migration potential compare with MCF-7 and OV2078 cells, as well as regulated epithelial-mesenchymal transition (EMT) marker. We found that HDAC4 and HADC7 mRNA are up regulated in MDA-MB-231 and C13* cells. Moreover, target HDAC4 and HDAC7 by TSA or shRNA block MDA-MB-231and C13* migration. These results reveal a new link between HDACs and EMT in the regulation of breast and ovarian cancer migration.
This study found that colon cancer cells express the chemokine receptor CCR4, which mediates migration of the cells in response to its ligand CCL17 (TARC) through the RhoA/Rho kinase signaling pathway. Quantitative RT-PCR and flow cytometry showed that the colon cancer cell lines HT-29 and AZ-97 expressed CCR4 at both the mRNA and protein levels. Stimulation with CCL17 induced dose-dependent migration of the colon cancer cells, which was inhibited by blocking CCR4 with an antibody or antagonist. CCL17 also increased mRNA levels of RhoA proteins and RhoA activation in the cells. Inhibition of Rho kinase or isoprenylation blocked CCL17-induced cell migration
The Effects of Genetic Alteration on Reprogramming of Fibroblasts into Induc...remedypublications2
Induced Pluripotent Stem Cells (iPSCs) can be generated from somatic cells by ectopic expression of
Yamanaka factors (
Oct4
,
Sox2
,
Klf4
and
c-Myc
) or combination of other factors. Genetic alteration
of fibroblasts exhibits an effect on reprogramming efficiency through multiple signaling pathways,
including epigenetic modifications, metabolic shifts, Mesenchymal-To-Epithelial Transition
(MET) and cell proliferation. In order to better understand the underlying mechanisms in cell fate
determination, in this review we will summarize several genetic alterations involved in the regulation
of reprogramming fibroblasts into iPSCs.
COTI-2 is a novel small molecule discovered by Critical Outcome Technologies Inc. that restores the function of mutant p53 proteins and negatively modulates the PI3K/AKT/mTOR cancer-related signaling pathway. It shows promise as an oral cancer therapy for cancers with p53 mutations or abnormalities in the PI3K/AKT/mTOR pathway, which include a broad range of common cancers. Preclinical studies demonstrate its safety and effectiveness against several cancer types. A Phase I clinical trial is currently underway for gynecological cancers.
Immunologic tumour models in NSCLC - Dr Catriona DowlingHannahMcCarthy31
Dr Dowling is a lecturer in biomedical sciences and is a lung cancer researcher at the University of Limerick. Dr Dowling's special research interests are immuno-metabolism and basic science in lung cancer.
This study developed a new mouse model that lacks all isoforms of the Trim24 gene. Mice with complete loss of Trim24 (Trim24-/-) spontaneously developed hepatic lipid accumulation, inflammation, fibrosis, and hepatocellular carcinoma without a high-fat diet or other induction methods. Trim24-/- mice had decreased expression of genes involved in oxidation, lipid metabolism, and increased expression of genes related to endoplasmic reticulum stress and cell cycle pathways. By 6 months of age, Trim24-/- mice exhibited macroscopic white liver lesions composed of steatosis and fibrosis that progressed to hepatocellular carcinoma, recapitulating features of non-alcoholic fatty liver disease in humans
1) Mice lacking the gene encoding miR-122a (Mir122a-/- mice) developed steatohepatitis, fibrosis, and hepatocellular carcinoma at a high frequency and in a sex-dependent manner similar to humans.
2) Mir122a-/- mice exhibited impaired lipid metabolism including reduced expression of the microsomal triglyceride transfer protein MTTP, contributing to steatosis.
3) Restoring MTTP or miR-122a expression in Mir122a-/- mice reduced disease manifestations by reversing steatosis, inflammation, and fibrosis and improving liver function.
1) The study found that the tumor protein p53 regulates the expression of the immune checkpoint protein PDL1 (programmed death ligand 1) via the microRNA miR-34.
2) Delivery of miR-34a in a mouse model of lung cancer using a liposomal formulation (MRX34) reduced PDL1 expression in tumors and increased tumor-infiltrating immune cells.
3) Combining MRX34 with radiation therapy further increased immune cell numbers in tumors and showed potential as a novel cancer therapeutic approach.
CXCR7 is induced by hypoxia and mediates glioma cell migration towards SDF-1a...Enrique Moreno Gonzalez
Glioblastomas, the most common and malignant brain tumors of the central nervous system, exhibit high invasive capacity, which hinders effective therapy. Therefore, intense efforts aimed at improved therapeutics are ongoing to delineate the molecular mechanisms governing glioma cell migration and invasion.
Comparative analysis of genome methylation in Thermotogae isolates from deep-...Thomas Haverkamp
The phylum Thermotogae is characterized by the presence of extensive horizontal gene transfer (HGT). Highly similar genes are shared between genomes of different Thermotogae genera, other phyla (Firmicutes) or other kingdoms such as the Archaea [1]. Many of these organisms proliferate in hot extreme environments such as oil fields and hydrothermal vents. How HGT functions in these ecosystems is unclear, but phages might play a role as a transfer agent of genetic material. Thermotogae genomes contain CRISPR repeats, which are part of the defence machinery against phages. Another defence mechanism against phages is the restriction modifications system and genes related to this are found as well in several Ther- motogae genomes. The restriction modification system uses methyltransferase proteins to methylate bases of the DNA strand. Under a phage attack, this system detects the non-meth- ylated foreign DNA and utilizes restriction enzymes to degrade invading DNA. With the advancement of single-molecule, real-time (SMRT) sequencing it has become possible to detect- ed N4-methylcytosine (m4C) and N6-methyladenine (m6A) bases in bacterial genomes. Here we use SMRT genome sequencing to compare four Thermotogae isolates from deep-sea hydrothermal vents and compare their defence system set-up, including CRISPRs and base modifications, in order to understand the probable response to invading DNA.

This study assessed the safety, tolerability, and immunogenicity of a polyvalent WT1 peptide vaccine in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Sixteen patients received at least one vaccination of four WT1 peptides designed to stimulate both CD4 and CD8 T-cell responses. Vaccinations were well-tolerated with no discontinuations due to toxicity. Two AML patients experienced relapse-free survival over 1 year, exceeding the duration of their first remission, suggesting potential clinical benefit from the vaccine. The vaccine engaged protective immune responses against WT1, warranting further clinical trials.
This clinical trial assessed the safety and immunogenicity of a polyvalent WT1 peptide vaccine in patients with acute myeloid leukemia (AML) in complete remission. Nine evaluable patients received six vaccinations over 12 weeks with four WT1 peptides plus adjuvants. WT1-specific T-cell responses were detected in seven of eight patients by assays such as ELISPOT and tetramer staining. The vaccine was found to be safely administered and induced immune responses against WT1. Further studies are needed to establish the role of vaccination as postremission therapy for AML.
This document summarizes research combining targeted inhibition of both BCR-ABL1 and STAT3 to induce synthetic lethality in therapy-resistant chronic myeloid leukemia (CML). The researchers discovered BP-5-087, a potent and selective inhibitor of the STAT3 SH2 domain that reduces STAT3 phosphorylation and activity. Computational modeling, biochemical assays, and testing on patient samples demonstrate that BP-5-087 directly binds STAT3. BP-5-087 restored sensitivity to tyrosine kinase inhibitors in imatinib-resistant CML progenitor cells and leukemic stem cells by inhibiting STAT3, which is activated in BCR-ABL1 kinase-independent resistance. These findings suggest dual inhibition of BCR-
Koehne, G., et al. Galinpepimut-S in multiple myeloma data – clinical updates...sellasq4
This document summarizes results from a phase 1/2 clinical trial testing galinpepimut-S (GPS), a Wilms' tumor 1 (WT1) peptide immunotherapeutic, in multiple myeloma patients following autologous stem cell transplantation. Nineteen patients received six doses of GPS followed by six booster doses. WT1-specific immune responses were detected in 16 of 18 patients. By 12 months post-transplant, 56.3% of patients had a minimal residual disease-negative complete response or very good partial response. The median progression-free survival was 23.6 months, compared to 9.3 months for similar high-risk patients receiving standard therapy alone. GPS was well-tolerated with
This study evaluated an adjuvant WT1 vaccine (SLS-001) for patients with malignant pleural mesothelioma after multimodality therapy. Seventy-eight patients received either the WT1 vaccine or a control immunotherapy every two weeks for six doses. The primary endpoint was one-year progression-free survival. The study was closed early due to futility in both arms. While injection site reactions were common, clinically significant severe events did not occur. Median overall survival was 24.8 months for the vaccine group and 16.6 months for the control, though the difference was not statistically significant. The WT1 vaccine induced CD4+ and CD8+ T cell responses and had a manageable safety profile. A
Transcriptome Analysis of Spontaneous PDFJanaya Shelly
This document summarizes an analysis of gene expression in mouse lung tumors using RNA sequencing. Five mouse lung tumors - two spontaneous and three genetically engineered - were analyzed along with normal lung tissue. The top expressing genes in each tumor type were identified and their biological functions analyzed. Spontaneous tumors were associated with homeostatic processes while engineered tumors exhibited genes related to metastasis and immune response. The study aims to gain insights into lung cancer genetics using mouse models.
This document discusses a study analyzing the distribution of promoter hypermethylation of the p16 gene in male and female colorectal cancer patients in Kashmir, India. The study found different p16 promoter hypermethylation profiles in male and female patients, with occurrence being more frequent in males than females, though not statistically significant. Promoter hypermethylation of p16 was significantly associated with colorectal cancer in both sexes. The study aimed to contribute to understanding the role of epigenetic changes in colorectal cancer development and progression.
The document identifies miR-27a as a potential tumor suppressor microRNA that is downregulated in leukemia. Functional experiments show that overexpression of miR-27a in leukemia cell lines inhibits cell growth and increases apoptosis. miR-27a is predicted to target several pro-apoptotic and cell cycle genes, and in vitro experiments confirm it directly binds to the 3'UTR of YWHAQ, a gene involved in apoptosis signaling. Further studies are needed to validate the tumor suppressor role of miR-27a in vivo and explore its potential as a therapeutic target or drug for leukemia treatment.
This document summarizes a study that designed synthetic analog peptides derived from the WT1 oncoprotein to improve human T-cell responses against it. The study introduced single amino acid substitutions at HLA-A0201 MHC binding positions in native WT1 peptide sequences. Several of the new analog peptides bound HLA-A0201 molecules better than the native sequences. Some analogs were also able to elicit stronger WT1-specific T-cell recognition and cytotoxic T lymphocyte responses compared to native sequences. Importantly, T cells stimulated with the analog peptides could cross-react with and kill cells expressing the native WT1 peptide sequence. The study concludes that analog peptides with increased immunogenicity may be potential cancer vaccine candidates.
May r.j.-et-al.-2007-clinical-cancer-researchSellasCorp
This document summarizes a study identifying three HLA class II peptide epitopes from the Wilms' tumor 1 (WT1) oncoprotein that stimulate CD4+ T cell responses. One peptide (122-140) also contains a previously identified CD8+ epitope (126-134) and was modified to improve its ability to induce both CD4+ and CD8+ T cell responses against WT1-expressing tumor cells. Dendritic cells pulsed with these WT1 peptides were able to stimulate peptide-specific CD4+ T cell responses and cross-priming experiments showed the dendritic cells could present the peptides after processing tumor cell lysates. These WT1 CD4+ peptides may be useful for inclusion in
Fatty liver index correlates with non-alcoholic fatty liver disease, but not ...Enrique Moreno Gonzalez
Fatty liver index (FLI) was recently established to predict non-alcoholic fatty liver disease (NAFLD) in general population, which is known to be associated with coronary artery atherosclerotic disease (CAD).
This study aims to investigate whether FLI correlates with NAFLD and with newly diagnosed CAD in a special Chinese population who underwent coronary angiography.
Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on...Enrique Moreno Gonzalez
Melanoma represents one of the most aggressive and therapeutically challenging malignancies as it often gives rise to metastases and develops resistance to classical chemotherapeutic agents. Although diverse therapies have been generated, no major improvement of the patient prognosis has been noticed. One promising alternative to the conventional therapeutic approaches currently available is the inactivation of proteins essential for survival and/or progression of melanomas by means of RNA interference. Survivin and cyclin B1, both involved in cell survival and proliferation and frequently deregulated in human cancers, are good candidate target genes for siRNA mediated therapeutics.
This study found that colon cancer cells express the chemokine receptor CCR4, which mediates migration of the cells in response to its ligand CCL17 (TARC) through the RhoA/Rho kinase signaling pathway. Quantitative RT-PCR and flow cytometry showed that the colon cancer cell lines HT-29 and AZ-97 expressed CCR4 at both the mRNA and protein levels. Stimulation with CCL17 induced dose-dependent migration of the colon cancer cells, which was inhibited by blocking CCR4 with an antibody or antagonist. CCL17 also increased mRNA levels of RhoA proteins and RhoA activation in the cells. Inhibition of Rho kinase or isoprenylation blocked CCL17-induced cell migration
The Effects of Genetic Alteration on Reprogramming of Fibroblasts into Induc...remedypublications2
Induced Pluripotent Stem Cells (iPSCs) can be generated from somatic cells by ectopic expression of
Yamanaka factors (
Oct4
,
Sox2
,
Klf4
and
c-Myc
) or combination of other factors. Genetic alteration
of fibroblasts exhibits an effect on reprogramming efficiency through multiple signaling pathways,
including epigenetic modifications, metabolic shifts, Mesenchymal-To-Epithelial Transition
(MET) and cell proliferation. In order to better understand the underlying mechanisms in cell fate
determination, in this review we will summarize several genetic alterations involved in the regulation
of reprogramming fibroblasts into iPSCs.
COTI-2 is a novel small molecule discovered by Critical Outcome Technologies Inc. that restores the function of mutant p53 proteins and negatively modulates the PI3K/AKT/mTOR cancer-related signaling pathway. It shows promise as an oral cancer therapy for cancers with p53 mutations or abnormalities in the PI3K/AKT/mTOR pathway, which include a broad range of common cancers. Preclinical studies demonstrate its safety and effectiveness against several cancer types. A Phase I clinical trial is currently underway for gynecological cancers.
Immunologic tumour models in NSCLC - Dr Catriona DowlingHannahMcCarthy31
Dr Dowling is a lecturer in biomedical sciences and is a lung cancer researcher at the University of Limerick. Dr Dowling's special research interests are immuno-metabolism and basic science in lung cancer.
This study developed a new mouse model that lacks all isoforms of the Trim24 gene. Mice with complete loss of Trim24 (Trim24-/-) spontaneously developed hepatic lipid accumulation, inflammation, fibrosis, and hepatocellular carcinoma without a high-fat diet or other induction methods. Trim24-/- mice had decreased expression of genes involved in oxidation, lipid metabolism, and increased expression of genes related to endoplasmic reticulum stress and cell cycle pathways. By 6 months of age, Trim24-/- mice exhibited macroscopic white liver lesions composed of steatosis and fibrosis that progressed to hepatocellular carcinoma, recapitulating features of non-alcoholic fatty liver disease in humans
1) Mice lacking the gene encoding miR-122a (Mir122a-/- mice) developed steatohepatitis, fibrosis, and hepatocellular carcinoma at a high frequency and in a sex-dependent manner similar to humans.
2) Mir122a-/- mice exhibited impaired lipid metabolism including reduced expression of the microsomal triglyceride transfer protein MTTP, contributing to steatosis.
3) Restoring MTTP or miR-122a expression in Mir122a-/- mice reduced disease manifestations by reversing steatosis, inflammation, and fibrosis and improving liver function.
1) The study found that the tumor protein p53 regulates the expression of the immune checkpoint protein PDL1 (programmed death ligand 1) via the microRNA miR-34.
2) Delivery of miR-34a in a mouse model of lung cancer using a liposomal formulation (MRX34) reduced PDL1 expression in tumors and increased tumor-infiltrating immune cells.
3) Combining MRX34 with radiation therapy further increased immune cell numbers in tumors and showed potential as a novel cancer therapeutic approach.
CXCR7 is induced by hypoxia and mediates glioma cell migration towards SDF-1a...Enrique Moreno Gonzalez
Glioblastomas, the most common and malignant brain tumors of the central nervous system, exhibit high invasive capacity, which hinders effective therapy. Therefore, intense efforts aimed at improved therapeutics are ongoing to delineate the molecular mechanisms governing glioma cell migration and invasion.
Comparative analysis of genome methylation in Thermotogae isolates from deep-...Thomas Haverkamp
The phylum Thermotogae is characterized by the presence of extensive horizontal gene transfer (HGT). Highly similar genes are shared between genomes of different Thermotogae genera, other phyla (Firmicutes) or other kingdoms such as the Archaea [1]. Many of these organisms proliferate in hot extreme environments such as oil fields and hydrothermal vents. How HGT functions in these ecosystems is unclear, but phages might play a role as a transfer agent of genetic material. Thermotogae genomes contain CRISPR repeats, which are part of the defence machinery against phages. Another defence mechanism against phages is the restriction modifications system and genes related to this are found as well in several Ther- motogae genomes. The restriction modification system uses methyltransferase proteins to methylate bases of the DNA strand. Under a phage attack, this system detects the non-meth- ylated foreign DNA and utilizes restriction enzymes to degrade invading DNA. With the advancement of single-molecule, real-time (SMRT) sequencing it has become possible to detect- ed N4-methylcytosine (m4C) and N6-methyladenine (m6A) bases in bacterial genomes. Here we use SMRT genome sequencing to compare four Thermotogae isolates from deep-sea hydrothermal vents and compare their defence system set-up, including CRISPRs and base modifications, in order to understand the probable response to invading DNA.

This study assessed the safety, tolerability, and immunogenicity of a polyvalent WT1 peptide vaccine in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Sixteen patients received at least one vaccination of four WT1 peptides designed to stimulate both CD4 and CD8 T-cell responses. Vaccinations were well-tolerated with no discontinuations due to toxicity. Two AML patients experienced relapse-free survival over 1 year, exceeding the duration of their first remission, suggesting potential clinical benefit from the vaccine. The vaccine engaged protective immune responses against WT1, warranting further clinical trials.
This clinical trial assessed the safety and immunogenicity of a polyvalent WT1 peptide vaccine in patients with acute myeloid leukemia (AML) in complete remission. Nine evaluable patients received six vaccinations over 12 weeks with four WT1 peptides plus adjuvants. WT1-specific T-cell responses were detected in seven of eight patients by assays such as ELISPOT and tetramer staining. The vaccine was found to be safely administered and induced immune responses against WT1. Further studies are needed to establish the role of vaccination as postremission therapy for AML.
This document summarizes research combining targeted inhibition of both BCR-ABL1 and STAT3 to induce synthetic lethality in therapy-resistant chronic myeloid leukemia (CML). The researchers discovered BP-5-087, a potent and selective inhibitor of the STAT3 SH2 domain that reduces STAT3 phosphorylation and activity. Computational modeling, biochemical assays, and testing on patient samples demonstrate that BP-5-087 directly binds STAT3. BP-5-087 restored sensitivity to tyrosine kinase inhibitors in imatinib-resistant CML progenitor cells and leukemic stem cells by inhibiting STAT3, which is activated in BCR-ABL1 kinase-independent resistance. These findings suggest dual inhibition of BCR-
Koehne, G., et al. Galinpepimut-S in multiple myeloma data – clinical updates...sellasq4
This document summarizes results from a phase 1/2 clinical trial testing galinpepimut-S (GPS), a Wilms' tumor 1 (WT1) peptide immunotherapeutic, in multiple myeloma patients following autologous stem cell transplantation. Nineteen patients received six doses of GPS followed by six booster doses. WT1-specific immune responses were detected in 16 of 18 patients. By 12 months post-transplant, 56.3% of patients had a minimal residual disease-negative complete response or very good partial response. The median progression-free survival was 23.6 months, compared to 9.3 months for similar high-risk patients receiving standard therapy alone. GPS was well-tolerated with
This study evaluated an adjuvant WT1 vaccine (SLS-001) for patients with malignant pleural mesothelioma after multimodality therapy. Seventy-eight patients received either the WT1 vaccine or a control immunotherapy every two weeks for six doses. The primary endpoint was one-year progression-free survival. The study was closed early due to futility in both arms. While injection site reactions were common, clinically significant severe events did not occur. Median overall survival was 24.8 months for the vaccine group and 16.6 months for the control, though the difference was not statistically significant. The WT1 vaccine induced CD4+ and CD8+ T cell responses and had a manageable safety profile. A
Transcriptome Analysis of Spontaneous PDFJanaya Shelly
This document summarizes an analysis of gene expression in mouse lung tumors using RNA sequencing. Five mouse lung tumors - two spontaneous and three genetically engineered - were analyzed along with normal lung tissue. The top expressing genes in each tumor type were identified and their biological functions analyzed. Spontaneous tumors were associated with homeostatic processes while engineered tumors exhibited genes related to metastasis and immune response. The study aims to gain insights into lung cancer genetics using mouse models.
This document discusses a study analyzing the distribution of promoter hypermethylation of the p16 gene in male and female colorectal cancer patients in Kashmir, India. The study found different p16 promoter hypermethylation profiles in male and female patients, with occurrence being more frequent in males than females, though not statistically significant. Promoter hypermethylation of p16 was significantly associated with colorectal cancer in both sexes. The study aimed to contribute to understanding the role of epigenetic changes in colorectal cancer development and progression.
The document identifies miR-27a as a potential tumor suppressor microRNA that is downregulated in leukemia. Functional experiments show that overexpression of miR-27a in leukemia cell lines inhibits cell growth and increases apoptosis. miR-27a is predicted to target several pro-apoptotic and cell cycle genes, and in vitro experiments confirm it directly binds to the 3'UTR of YWHAQ, a gene involved in apoptosis signaling. Further studies are needed to validate the tumor suppressor role of miR-27a in vivo and explore its potential as a therapeutic target or drug for leukemia treatment.
This document summarizes a study that designed synthetic analog peptides derived from the WT1 oncoprotein to improve human T-cell responses against it. The study introduced single amino acid substitutions at HLA-A0201 MHC binding positions in native WT1 peptide sequences. Several of the new analog peptides bound HLA-A0201 molecules better than the native sequences. Some analogs were also able to elicit stronger WT1-specific T-cell recognition and cytotoxic T lymphocyte responses compared to native sequences. Importantly, T cells stimulated with the analog peptides could cross-react with and kill cells expressing the native WT1 peptide sequence. The study concludes that analog peptides with increased immunogenicity may be potential cancer vaccine candidates.
May r.j.-et-al.-2007-clinical-cancer-researchSellasCorp
This document summarizes a study identifying three HLA class II peptide epitopes from the Wilms' tumor 1 (WT1) oncoprotein that stimulate CD4+ T cell responses. One peptide (122-140) also contains a previously identified CD8+ epitope (126-134) and was modified to improve its ability to induce both CD4+ and CD8+ T cell responses against WT1-expressing tumor cells. Dendritic cells pulsed with these WT1 peptides were able to stimulate peptide-specific CD4+ T cell responses and cross-priming experiments showed the dendritic cells could present the peptides after processing tumor cell lysates. These WT1 CD4+ peptides may be useful for inclusion in
Fatty liver index correlates with non-alcoholic fatty liver disease, but not ...Enrique Moreno Gonzalez
Fatty liver index (FLI) was recently established to predict non-alcoholic fatty liver disease (NAFLD) in general population, which is known to be associated with coronary artery atherosclerotic disease (CAD).
This study aims to investigate whether FLI correlates with NAFLD and with newly diagnosed CAD in a special Chinese population who underwent coronary angiography.
Sticky siRNAs targeting survivin and cyclin B1 exert an antitumoral effect on...Enrique Moreno Gonzalez
Melanoma represents one of the most aggressive and therapeutically challenging malignancies as it often gives rise to metastases and develops resistance to classical chemotherapeutic agents. Although diverse therapies have been generated, no major improvement of the patient prognosis has been noticed. One promising alternative to the conventional therapeutic approaches currently available is the inactivation of proteins essential for survival and/or progression of melanomas by means of RNA interference. Survivin and cyclin B1, both involved in cell survival and proliferation and frequently deregulated in human cancers, are good candidate target genes for siRNA mediated therapeutics.
Association between variations in the fat mass and obesity-associated gene an...Enrique Moreno Gonzalez
It is clear that genetic variations in the fat mass and obesity-associated (FTO) gene affect body mass index and the risk of obesity. Given the mounting evidence showing a positive association between obesity and pancreatic cancer, this study aimed to investigate the relation between variants in the FTO gene, obesity and pancreatic cancer risk.
Intraepithelial lymphocyte distribution differs between the bulb and the seco...Enrique Moreno Gonzalez
Evaluation of intraepithelial duodenal lymphocytosis (IDL) is important in celiac disease (CD). There is no established cut-off value for increased number of IELs in the bulb. We therefore investigated the relation between IEL counts in the bulb and duodenal specimens in non-celiac subjects.
Implication from thyroid function decreasing during chemotherapy in breast ca...Enrique Moreno Gonzalez
Thyroid hormones have been shown to regulate breast cancer cells growth, the absence or reduction of thyroid hormones in cells could provoke a proliferation arrest in G0-G1 or weak mitochondrial activity, which makes cells insensitive to therapies for cancers through transforming into low metabolism status. This biological phenomenon may help explain why treatment efficacy and prognosis vary among breast cancer patients having hypothyroid, hyperthyroid and normal function. Nevertheless, the abnormal thyroid function in breast cancer patients has been considered being mainly caused by thyroid diseases, few studied influence of chemotherapy on thyroid function and whether its alteration during chemotherapy can influence the respose to chemotherapy is still unclear. So, we aimed to find the alterations of thyroid function and non-thyroidal illness syndrome (NTIS) prevalence druing chemotherapy in breast cancer patients, and investigate the influence of thyroid hormones on chemotherapeutic efficacy.
Clinical features and outcome of cryptogenic hepatocellular carcinoma compare...Enrique Moreno Gonzalez
Cryptogenic hepatocellular carcinoma (HCC) is thought to arise due to non-alcoholic fatty liver disease (NAFLD). This study investigated the prevalence, clinical features, and outcomes of cryptogenic HCC and compared them with those of HCC related to hepatitis B virus infection (HBV-HCC), hepatitis C virus infection (HCV-HCC), and alcohol (ALCHCC) in Korea.
Antibiotic exposure and the development of coeliac disease: a nationwide case...Enrique Moreno Gonzalez
The intestinal microbiota has been proposed to play a pathogenic role in coeliac disease (CD). Although antibiotics are common environmental factors with a profound impact on intestinal microbiota, data on antibiotic use as a risk factor for subsequent CD development are scarce.
Optimal schedule of Bacillus Calmette-Guerin for non-muscle-invasive bladder ...Enrique Moreno Gonzalez
To explore the necessity of maintenance, efficacy of low-dose and superiority of various combination therapies of Bacillus Calmette-Guérin (BCG) in treatment of superficial bladder cancer (BCa).
Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung c...Enrique Moreno Gonzalez
This document summarizes a research study that investigated the activation of Wnt-2 signaling through the Frizzled-8 receptor in non-small cell lung cancer (NSCLC). The study found a correlation between increased expression of Wnt-2 and Frizzled-8 in lung cancer tissue samples. A novel dominant-negative Wnt-2 construct (dnhWnt-2) inhibited Wnt-2 signaling activation and reduced colony formation of NSCLC cells in vitro and tumor growth in a mouse xenograft model. The dnhWnt-2 construct may provide a new therapeutic approach for targeting the Wnt pathway in lung cancer.
Molecular mechanisms of action and potential biomarkers of growth inhibition ...Enrique Moreno Gonzalez
Molecular targeted therapy has emerged as a promising treatment of Hepatocellular carcinoma (HCC). One potential target is the Src family Kinase (SFK). C-Src, a non-receptor tyrosine kinase is a critical link of multiple signal pathways that regulate proliferation, invasion, survival, metastasis, and angiogenesis. In this study, we evaluated the effects of a novel SFK inhibitor, dasatinib (BMS-354825), on SFK/FAK/p130CAS, PI3K/PTEN/Akt/mTOR, Ras/Raf/MAPK and Stats pathways in 9 HCC cell lines.
This research article investigates the effects of the natural flavonoid luteolin on colon cancer cells. The researchers found that physiological concentrations of luteolin induce apoptosis in colon cancer cells by increasing levels of the sphingolipid ceramide. Luteolin inhibits the conversion of ceramide to more complex sphingolipids and disrupts the transport of ceramide between organelles. These effects are mediated by luteolin's ability to inhibit the enzymes sphingosine kinase 2 and Akt, thereby reducing levels of the molecule sphingosine-1-phosphate which normally promotes cell survival. Overall, the study reveals that luteolin exerts anticancer effects by targeting the balance between ceramide and sphingosine-1-
- The study examined malondialdehyde (MDA) levels and hematological parameters in 31 newly diagnosed cervical cancer patients at a hospital in India.
- MDA levels, which indicate oxidative stress, were found to be significantly higher in cervical cancer patients compared to healthy volunteers. MDA levels also differed between cancer grades.
- Hematological analysis found reduced red blood cell count and hemoglobin levels and increased white blood cell count in cervical cancer patients relative to normal levels.
- The results suggest that oxidative stress and hematological abnormalities are present at the initial clinical presentation of cervical cancer patients and that MDA may be a predictive marker for disease progression. Controlling oxidative stress and improving nutrition could help cervical cancer treatment
1) Plumbagin (PL), derived from plants, inhibits prostate tumor development in mice lacking the tumor suppressor PTEN (Pten-KO mice), a model for prostate cancer.
2) PL treatment decreased expression of proteins involved in prostate cancer progression (PKCε, STAT3, AKT) and epithelial-to-mesenchymal transition (EMT).
3) Dietary PL inhibited primary prostate tumor growth and castration-resistant prostate cancer growth in Pten-KO mice, potentially by inhibiting PKCε, STAT3, AKT, and EMT markers.
This study found that oncogenic Ras sensitizes normal human cells to TRAIL-induced apoptosis by enhancing caspase 8 recruitment and activation at the DISC. Specifically:
1) Normal and immortalized human cells were resistant to TRAIL, while Ras-transformed cells were susceptible, undergoing apoptosis.
2) Ras transformation potentiated TRAIL-induced cleavage of caspase 8 and its substrates Bid and plectin, indicating enhanced caspase 8 activation.
3) Ras enhanced the recruitment of caspase 8 to the TRAIL death-inducing signaling complex (DISC), allowing more efficient caspase 8 cleavage and activation of the apoptotic pathway.
The document summarizes research on using a small molecule mimetic of the Sin3A interaction domain (SID) decoy (C16) alone or in combination with retinoic acid receptor alpha (RARα) agonists to treat triple negative breast cancer (TNBC). The key findings are:
1) C16 increases expression of RARβ2 and endogenous retinoic acid levels, activating RAR target gene expression.
2) C16 combined with the RARα agonist AM80 strongly activates RARE-driven reporter gene expression more than either treatment alone.
3) In 3D culture, C16 combined with RARα agonists induces acinar morphogenesis and inhibits tumors
Identification of the Enrichment Pathways of Catalase in Multiple Primary Tumorsdaranisaha
Reactive oxygen species (ROS) has been detected in almost all cancers, which it involves many aspects of carcinogenesis and tumor progression. We previously reported a novel oncogenic role of manganese superoxide dismutase (MnSOD; SOD2) in invasive lung adenocarcinoma (LUAD) by upregulating forkhead box protein M1 (FOXM1) and matrix metalloproteinase-2 (MMP2) expression. In this study, we used a comprehensive analysis and further evaluated the effects of a hydrogen peroxide (H2O2) scavenger, catalase (CAT) in The Cancer Genome Atlas (TCGA) datasets of the different cancer types.
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoMauricio Lema
Ponencia en el VII Congreso internacional de coloproctología, Bogotá, 18.08.2016. Con énfasis en los estudios recientes en terapia antiangiogénica, y el impacto del lado del primario en el pronóstico (y aspectos predictivos) de la enfermedad metastásica.
Higher expression of SATB2 in hepatocellular carcinoma of African Americans d...rakeshsrivastava89
Abstract
In the United States, Hepatocellular Carcinoma (HCC) incidence has tripled over the past two decades. The disease has disproportionately affected minority and disadvantaged
populations. The purpose of this study was to examine the expression of SATB2 gene in HCC cells derived from African Americans (AA) and Caucasian Americans (CA) and assess its oncogenic potential by measuring cell viability, spheroid
formation, epithelial‐mesenchymal transition (EMT), stem cell markers and pluripotency maintaining factors in cancer stem cells (CSCs). We compared the expression of SATB2 in human primary hepatocytes, HCC cells derived from AA and CA, and
HCC CSCs. Hepatocellular carcinoma cells derived from AA expressed the higher level of SATB2 than those from CA. By comparison, normal human hepatocytes did
not express SATB2. Higher expression of SATB2 in HCC cells from AA was associated with greater growth rate, cell viability, colony formation and EMT characteristics than those from CA. Knockout of SATB2 in CSCs by Crispr/Cas9 technique significantly inhibited the expression of SATB2 gene, stem cell markers (CD24, CD44 and CD133), pluripotency maintaining factors (c‐Myc, KLF4, SOX2 and OCT4), and EMT
compared with non‐targeting control group. The expression of SATB2 was negatively correlated with miR34a. SATB2 rescued the miR‐34a‐mediated inhibition of CSC's viability. These data suggest that SATB2 is an oncogenic factor, and its higher expression may explain the disparity in HCC outcomes among AA.
Wei Yu1 | Sanjit K. Roy2 | Yiming Ma1 | Thomas A. LaVeist3 | Sharmila Shankar1,2,4 |
Rakesh K. Srivastava1,2,4
This study investigated the role of integrin-linked kinase (ILK) in bladder cancer invasion and progression. The researchers found that invasive bladder cancer cells have high ILK expression, which plays a role in epithelial-to-mesenchymal transition by regulating E-cadherin expression. Knocking down ILK in invasive bladder cancer cells suppressed cell invasion by regulating E-cadherin and MMP-9. Analysis of human bladder cancer samples also showed that high ILK expression correlates with increased invasiveness. Therefore, this study suggests that ILK is important for EMT in bladder cancer and could be a new therapeutic target to suppress tumor progression.
This document summarizes research finding that elevated activity of the Akt protein protects prostate cancer LNCaP cells from apoptosis induced by TRAIL (tumor necrosis factor-related apoptosis-inducing ligand). The researchers found that LNCaP cells have high constitutive Akt activity due to lack of the PTEN lipid phosphatase. Inhibiting PI3-kinase, which activates Akt, sensitized LNCaP cells to TRAIL-induced apoptosis. TRAIL alone activated caspases 8 and XIAP in LNCaP cells but failed to induce full apoptosis. Combining TRAIL with Akt inhibitors allowed cleavage of BID and subsequent mitochondrial apoptosis steps. Akt inhibition of BID cleavage appears to mediate the protective effect
Radiotherapy promotes the polarization of tumor-associated macrophages (TAMs) in mice with Lewis lung cancer into anti-tumor M1 macrophages. This is accompanied by increased expression of the long non-coding RNA lincRNA-p21 in the TAMs. TAMs exposed to radiation therapy suppress the viability and invasion of Lewis lung cancer cells in culture. Overexpression of lincRNA-p21 in TAMs enhances their anti-tumor effects, while decreasing lincRNA-p21 reduces the effects of radiation therapy, suggesting lincRNA-p21 plays a key role in the anti-tumor actions of radiotherapy in lung cancer.
Resveratrol induces apoptotic death in human glioma U251 cells through multiple signaling pathways. Resveratrol treatment leads to dose- and time-dependent cell death, as measured by lactate dehydrogenase release and DNA fragmentation assays. It activates caspase-3 and increases cleavage of poly(ADP-ribose) polymerase. Resveratrol also induces cytochrome c release from mitochondria, caspase-9 activation, Bax expression/translocation, and G0/G1 cell cycle arrest. These findings suggest resveratrol may be an attractive anticancer agent for treating gliomas.
Management of colorectal cancers in older peopleSpringer
This document discusses genetic alterations in colorectal cancer between younger and older patients. It begins by providing background on the multistep model of colorectal cancer development and the genetic mutations that drive each step, such as APC, TP53, and KRAS. It then notes limited data on differences in genetic alterations between younger and older CRC patients. The document goes on to discuss aging and theories of aging, focusing on pathways such as insulin/IGF-1, TOR, AMP kinase, and sirtuins that may affect longevity when inhibited. It also discusses telomere length differences between younger and older CRC patients and prospects for human anti-aging interventions.
Lipocalin 2 as a Potential Diagnostic and/or Prognostic Biomarker in Prostate...JohnJulie1
Lipocalin 2 (LCN2) is a 25 kDa secreted protein, initially purified from neutrophil granules, and mainly expressed in immune cells, hepatocytes, renal cells, prostate, cells of the respiratory tract and cardiomyocytes. LCN2 belongs to the family of lipocalins known for their ability to traffic small hydrophobic molecules such as lipids and retinoids
Lipocalin 2 as a Potential Diagnostic and/or Prognostic Biomarker in Prostate...AnonIshanvi
Lipocalin 2 (LCN2) is a 25 kDa secreted protein, initially purified from neutrophil granules, and mainly expressed in immune cells, hepatocytes, renal cells, prostate, cells of the respiratory tract and cardiomyocytes. LCN2 belongs to the family of lipocalins known for their ability to traffic small hydrophobic molecules such as lipids and retinoids...
Lipocalin 2 as a Potential Diagnostic and/or Prognostic Biomarker in Prostate...daranisaha
This document summarizes research on lipocalin 2 (LCN2) as a potential diagnostic and prognostic biomarker for prostate, lung, and liver cancer. LCN2 is a protein that plays roles in iron transport, bacterial infection response, and cancer progression. Studies have found both increased and decreased LCN2 expression in different cancer types. For prostate cancer, LCN2 levels are higher in tumor tissue and blood of patients compared to healthy controls. Higher LCN2 also correlates with more advanced disease stages and reduced survival. In lung and liver cancer, LCN2 expression varies but may also have potential as a diagnostic or prognostic biomarker. The review discusses molecular pathways through which LCN2 impacts cancer development and clinical findings regarding its role in prognosis and
Lipocalin 2 (LCN2) is a 25 kDa secreted protein, initially purified from neutrophil granules,
and mainly expressed in immune cells, hepatocytes, renal cells, prostate, cells of the respiratory
tract and cardiomyocytes. LCN2 belongs to the family of lipocalins known for their ability to
traffic small hydrophobic molecules such as lipids and retinoids. Due to its ability to sequester
iron-containing bacterial siderophores, LCN2 plays an essential part of the innate immunity as
well as the regulation of the cellular iron metabolism
Similar to The cysteinyl leukotriene 2 receptor contributes to all-trans retinoic acid-induced differentiation of colon cancer cells (20)
Incidence of pneumonia and risk factors among patients with head and neck can...Enrique Moreno Gonzalez
This study investigated the incidence and patient- and treatment-related risk factors related to pneumonia acquired during radiotherapy (PNRT) in head and neck cancer (HNC) patients.
Gene expression analysis of a Helicobacter pyloriinfected and high-salt diet-...Enrique Moreno Gonzalez
Helicobacter pylori (H. pylori) infection and excessive salt intake are known as important risk factors for stomach cancer in humans. However, interactions of these two factors with gene expression profiles during gastric carcinogenesis remain unclear. In the present study, we investigated the global gene expression associated with stomach carcinogenesis and prognosis of human gastric cancer using a mouse model.
Acute myeloid leukemia (AML) is a hematopoietic malignancy with a dismal outcome in the majority of cases. A detailed understanding of the genetic alterations and gene expression changes that contribute to its pathogenesis is important to improve prognostication, disease monitoring, and therapy. In this context, leukemia-associated misexpression of microRNAs (miRNAs) has been studied, but no coherent picture has emerged yet, thus warranting further investigations.
Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable. However, preclinical experimental data explaining the interaction mechanism(s) are lacking. Our objective is to investigate the anticancer efficacy and mechanism of combined sorafenib and 5-FU therapy in vitro in HCC cell lines MHCC97H and SMMC-7721.
Differences in microRNA expression during tumor development in the transition...Enrique Moreno Gonzalez
The prostate is divided into three glandular zones, the peripheral zone (PZ), the transition zone (TZ), and the central zone. Most prostate tumors arise in the peripheral zone (70-75%) and in the transition zone (20-25%) while only 10% arise in the central zone. The aim of this study was to investigate if differences in miRNA expression could be a possible explanation for the difference in propensity of tumors in the zones of the prostate.
Multicentric and multifocal versus unifocal breast cancer: differences in the...Enrique Moreno Gonzalez
This study compared the expression of E-cadherin, β-catenin, and MUC1 in multicentric/multifocal breast cancers versus unifocal breast cancers of identical tumor size and grade. The study found significantly downregulated expression of E-cadherin in multicentric/multifocal cancers compared to unifocal cancers. In contrast, no significant differences were seen in β-catenin expression between the two groups. Within the unifocal group, E-cadherin and β-catenin expression were positively correlated, but this was not seen in the multicentric/multifocal group. The results suggest multicentric/multifocal and unifocal breast cancers differ in E-
The life in sight application study (LISA): design of a randomized controlled...Enrique Moreno Gonzalez
It is widely recognized that spiritual care plays an important role in physical and psychosocial well-being of cancer patients, but there is little evidence based research on the effects of spiritual care. We will conduct a randomized controlled trial on spiritual care using a brief structured interview scheme supported by an e-application. The aim is to examine whether an assisted reflection on life events and ultimate life goals can improve quality of life of cancer patients.
Clinical and experimental studies regarding the expression and diagnostic val...Enrique Moreno Gonzalez
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a multifunctional Ig-like cell adhesion molecule that has a wide range of biological functions. According to previous reports, serum CEACAM1 is dysregulated in different malignant tumours and associated with tumour progression. However, the serum CEACAM1 expression in nonsmall-cell lung carcinomas (NSCLC) is unclear. The different expression ratio of CEACAM1-S and CEACAM1-L isoform has seldom been investigated in NSCLC. This research is intended to study the serum CEACAM1 and the ratio of CEACAM1-S/L isoforms in NSCLC.
Assessment of preoperative exercise capacity in hepatocellular carcinoma pati...Enrique Moreno Gonzalez
Cardiopulmonary exercise testing measures oxygen uptake at increasing levels of work and predicts cardiopulmonary performance under conditions of stress, such as after abdominal surgery. Dynamic assessment of preoperative exercise capacity may be a useful predictor of postoperative prognosis. This study examined the relationship between preoperative exercise capacity and event-free survival in hepatocellular carcinoma (HCC) patients with chronic liver injury who underwent hepatectomy.
Overexpression of YAP 1 contributes to progressive features and poor prognosi...Enrique Moreno Gonzalez
Yes-associated protein 1 (YAP 1), the nuclear effector of the Hippo pathway, is a key regulator of organ size and a candidate human oncogene in multiple tumors. However, the expression dynamics of YAP 1 in urothelial carcinoma of the bladder (UCB) and its clinical/prognostic significance are unclear.
Abnormal expression of Pygopus 2 correlates with a malignant phenotype in hum...Enrique Moreno Gonzalez
Pygopus 2 (Pygo2) is a Pygo family member and an important component of the Wnt signaling transcriptional complex. Despite this data, no clinical studies investigating Pygo2 expression in lung cancer have yet been reported.
Differentiation of irradiation and cetuximab induced skin reactions in patien...Enrique Moreno Gonzalez
In order to improve the clinical outcome of patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) not being capable to receive platinum-based chemoradiation, radiotherapy can be intensified by addition of cetuximab, a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR). The radioimmunotherapy with cetuximab is a feasible treatment option showing a favourable toxicity profile. The most frequent side effect of radiotherapy is radiation dermatitis, the most common side effect of treatment with cetuximab is acneiform rash. Incidence and severity of these frequent, often overlapping and sometimes limiting skin reactions, however, are not well explored. A clinical and molecular differentiation between radiogenic skin reactions and skin reactions caused by cetuximab which may correlate with outcome, have never been described before.
Cholestasis induces reversible accumulation of periplakin in mouse liverEnrique Moreno Gonzalez
Periplakin (PPL) is a rod-shaped cytolinker protein thought to connect cellular adhesion junctional complexes to cytoskeletal filaments. PPL serves as a structural component of the cornified envelope in the skin and interacts with various types of proteins in cultured cells; its level decreases dramatically during tumorigenic progression in human epithelial tissues. Despite these intriguing observations, the physiological roles of PPL, especially in noncutaneous tissues, are still largely unknown. Because we observed a marked fluctuation of PPL expression in mouse liver in association with the bile acid receptor farnesoid X receptor (FXR) and cholestasis, we sought to characterize the role of PPL in the liver and determine its contributions to the etiology and pathogenesis of cholestasis.
Functional p53 is required for rapid restoration of daunorubicin-induced lesi...Enrique Moreno Gonzalez
This document summarizes a research article that studied the role of p53 in daunorubicin (DNR)-induced lesions in the spleen. The key findings were:
1) DNR treatment caused more rapid cell death and weight loss in the spleens of wild type mice compared to p53-null mice.
2) While wild type mouse spleens recovered normal morphology 8 days after DNR treatment, p53-null mouse spleens still had large necrotic lesions.
3) DNR treatment increased p21 levels in wild type mice but not p53-null mice, indicating p53 is required for p21 induction.
4) The results suggest p53
Post-diagnosis hemoglobin change associates with overall survival of multiple...Enrique Moreno Gonzalez
Anemia refers to low hemoglobin (Hb) level and is a risk factor of cancer patient survival. The National Comprehensive Cancer Network recently suggested that post-diagnosis Hb change, regardless of baseline Hb level, indicates the potential presence of anemia. However, there is no epidemiological study evaluating whether Hb change has direct prognostic values for cancer patients at the population level.
Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation car...Enrique Moreno Gonzalez
Women with mutations in BRCA1 or BRCA2 are at high risk of developing breast cancer and, in British Columbia, Canada, are offered screening with both magnetic resonance imaging (MRI) and mammography to facilitate early detection. MRI is more sensitive than mammography but is more costly and produces more false positive results. The purpose of this study was to calculate the cost-effectiveness of MRI screening for breast cancer in BRCA1/2 mutation carriers in a Canadian setting.
Impaired mitochondrial beta-oxidation in patients with chronic hepatitis C: r...Enrique Moreno Gonzalez
Hepatic steatosis is often seen in patients with chronic hepatitis C (CH-C). It is still unclear whether these patients have an impaired mitochondrial β-oxidation. In this study we assessed mitochondrial β-oxidation in CH-C patients by investigating ketogenesis during fasting.
Este documento presenta la laudatio del Dr. Enrique Moreno González, quien recibe el grado de Doctor Honoris Causa de la Universidad de Málaga. Resalta la trayectoria académica y profesional del Dr. Moreno, incluyendo sus logros en cirugía hepática y de trasplantes, sus cargos y distinciones, y su dedicación a la enseñanza. El orador destaca al Dr. Moreno como pionero quirúrgico, maestro, y persona comprometida con mejorar la atención médica a través
Environment inside even a small tumor is characterized by total (anoxia) or partial oxygen deprivation, hypoxia. It has been shown that radiotherapy and some conventional chemotherapies may be less effective in hypoxia, and therefore it is important to investigate how different drugs act in different microenvironments. In this study we perform a large screening of the effects of 19 clinically used or experimental chemotherapeutic drugs on four different cell lines in conditions of normoxia, hypoxia and anoxia.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
10 Benefits an EPCR Software should Bring to EMS Organizations Traumasoft LLC
The benefits of an ePCR solution should extend to the whole EMS organization, not just certain groups of people or certain departments. It should provide more than just a form for entering and a database for storing information. It should also include a workflow of how information is communicated, used and stored across the entire organization.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
2. The cysteinyl leukotriene 2 receptor contributes to
all-trans retinoic acid-induced differentiation of
colon cancer cells
Astrid M Bengtsson2,†
Email: astrid.bengtsson@med.lu.se
Gunilla Jönsson1,†
Email: gunilla_2.jonsson@med.lu.se
Cecilia Magnusson1
Email: cecilia.axelsson@med.lu.se
Tavga Salim1
Email: tavga.salim@med.lu.se
Cecilia Axelsson1
Email: anita.sjolander@med.lu.se
Anita Sjölander1*
*
Corresponding author
Email: anita.sjolander@med.lu.se
1
Department of Laboratory Medicine, Cell and Experimental Pathology, Lund
University, Malmö University Hospital, SE-205 02, Malmö, Sweden
2
Present name and address: Astrid Friborg at Berries by Astrid, Stockholm,
Sweden
†
Equal contributors.
Abstract
Background
Cysteinyl leukotrienes (CysLTs) are potent pro-inflammatory mediators that are increased in
samples from patients with inflammatory bowel diseases (IBDs). Individuals with IBDs have
enhanced susceptibility to colon carcinogenesis. In colorectal cancer, the balance between the
pro-mitogenic cysteinyl leukotriene 1 receptor (CysLT1R) and the differentiation-promoting
cysteinyl leukotriene 2 receptor (CysLT2R) is lost. Further, our previous data indicate that
patients with high CysLT1R and low CysLT2R expression have a poor prognosis. In this
study, we examined whether the balance between CysLT1R and CysLT2R could be restored
by treatment with the cancer chemopreventive agent all-trans retinoic acid (ATRA).
3. Methods
To determine the effect of ATRA on CysLT2R promoter activation, mRNA level, and protein
level, we performed luciferase gene reporter assays, real-time polymerase chain reactions,
and Western blots in colon cancer cell lines under various conditions.
Results
ATRA treatment induces CysLT2R mRNA and protein expression without affecting
CysLT1R levels. Experiments using siRNA and mutant cell lines indicate that the up-
regulation is retinoic acid receptor (RAR) dependent. Interestingly, ATRA also up-regulates
mRNA expression of leukotriene C4 synthase, the enzyme responsible for the production of
the ligand for CysLT2R. Importantly, ATRA-induced differentiation of colorectal cancer cells
as shown by increased expression of MUC-2 and production of alkaline phosphatase, both of
which could be reduced by a CysLT2R-specific inhibitor.
Conclusions
This study identifies a novel mechanism of action for ATRA in colorectal cancer cell
differentiation and demonstrates that retinoids can have anti-tumorigenic effects through their
action on the cysteinyl leukotriene pathway.
Keywords
All-trans retinoic acid (ATRA), CysLT2R, Leukotriene, Leukotriene receptor, Colon cancer,
Inflammation
Background
Individuals with inflammatory bowel diseases (IBD) have a 30-50% increased risk of
developing colorectal cancer [1,2]. The pro-inflammatory cysteinyl leukotrienes (CysLTs)
LTC4, LTD4, and LTE4 are derived from arachidonic acid through the actions of 5-
lipoxygenase and leukotriene C4 synthase (LTC4S) [3]. The CysLTs can induce smooth
muscle constriction, vascular leakage, and eosinophil recruitment in inflammatory diseases
such as asthma and rhinitis (reviewed in [4]). High levels of leukotrienes have been detected
in urine from patients with IBDs including ulcerative colitis and Crohn’s disease [5,6], and
treatment with the 5-lipoxygenase inhibitor Zileuton significantly alleviates IBD symptoms
[7]. Importantly, an increased risk for colorectal cancer has been observed in IBD patients
[2].
CysLT signaling is initiated when a ligand binds one of the two different G-protein-coupled
receptors: CysLT1R, CysLT2R [8,9]. Activation of the CysLT1R triggers signaling through
either or both the Gq- and the Gi-protein depending on the cell type, most commonly through
Gq [10-12]. We have shown that LTD4 via CysLT1R can induce both Erk phosphorylation
and protein kinase C activation that is involved in the regulation of the calcium signal
[13,14]. These activities lead to increased proliferation, survival, and phosphatidylinositol 3-
kinase- and Rac-dependent migration of colorectal cancer cells [15-17]. In contrast, CysLT2R
promotes colorectal cancer cell differentiation by increasing the activity of the intestinal
4. brush border enzymes alkaline phosphatase and aminopeptidase N [18]. The two receptors
also have opposite functions in mast cells, where CysLT2R negatively regulates the mitogenic
responses of CysLT1R [19]. The combination of high CysLT1R expression and low CysLT2R
expression in colon cancer specimens is correlated with poor survival prognosis and disease
outcome [18,20].
Vitamin A (retinol) and its metabolites are commonly referred to as retinoids. Retinoids play
important roles in embryonic development, vision, and as cancer chemopreventive agents
(see review [21,22] ). All-trans retinoic acid (ATRA) is a potent metabolite of vitamin A and
is successfully used to treat patients with acute promyelocytic leukemia [23]. In clinical trials,
retinoids have also shown promising results in head and neck, skin, ovarian, prostate, and
lung cancer [23]. ATRA has also had positive results in animal models for cancer. For
instance, rats on a low-fat diet supplemented with vitamin A have a reduced tumor incidence
[24]. Moreover, retinoids are effective in reducing azoxymethane-induced aberrant crypt foci
and colon tumors in rats [25]. ATRA treatment also reduced tumor growth 40–60% in
athymic mice implanted with HT-29 colon carcinoma cells [26]. In human colon cancer cell
lines, ATRA is capable of inducing growth inhibition, apoptosis, and differentiation [27].
ATRA exerts its effects through heterodimers of retinoic acid receptors (RARs) and retinoid
X receptors (RXRs), which are transcription factors of the nuclear receptor family [23]. All of
the known RAR isoforms (α, β, and γ) are expressed in colorectal cancer cell lines [28]. The
RAR/RXR heterodimers bind constitutively to retinoic acid response elements (RAREs) in
promoters of genes; these are characterized by two consensus half sites [PuG(G/T)TCA]
generally arranged as direct repeats separated by 2 to 5 nucleotides [23]. Upon ligand
binding, coactivators of the p160 family are recruited to replace the corepressors SMRT and
NCoR, and transcription is initiated [23].
We found sequences in the CysLT2R promoter region that were identical to RAREs reported
in the literature and hypothesized that treatment of colorectal cancer cells with ATRA would
affect the expression of CysLT2R. Furthermore, we investigated whether ATRA-induced
colon cancer cell differentiation was dependent on CysLT2R. LTC4S conjugates LTA4 with
glutathione to form LTC4 [3], and is induced by ATRA in rat basophilic leukemia cells and
associated with subsequent cell differentiation [29]. In addition to CysLT2R, LTC4S could be
induced by ATRA in colon cancer cells. It is well established that retinoids are effective
inducers of differentiation in cancer cells, but few studies have addressed the pathways that
mediate these effects.
Methods
Reagents
LTC4 was obtained from Cayman Chemicals Co. (Ann Arbor, MI); AP 100984 was a gift
from Jilly F. Evans (Amira Pharmaceuticals); and Lipofectamine 2000, Lipofectamine LTX,
and Opti-MEM were from Invitrogen (Carlsbad, CA). Hybond polyvinylidene difluoride
(PVDF) membranes were from Amersham Biosciences (Little Chalfont, Bucks, UK) and
Mini-PROTEAN TGX gels, Immun-blot PVDF membranes and Immun Star Western C were
from Biorad (Hercules, CA). The rabbit polyclonal CysLT1R and CysLT2R antibodies were
obtained from Innovagen (Lund, Sweden). The antibodies RARα C-20 (sc-551), RARβ C-19
(sc-552) and Lamin B C-20 (sc-6216), were purchased from Santa Cruz Biotechnology
5. (Santa Cruz, CA). The secondary peroxidase-conjugated goat anti-rabbit, rabbit anti-goat and
anti-mouse antibodies were purchased from Dako Cytomation (Glostrup, Denmark). The
caspase-3 fluorometric substrate was obtained from Upstate (Lake Placid, NY). All other
reagents were obtained from Sigma Chemicals (St Louis, MO).
Cell culture
The colon cancer cell lines Caco-2, SW480 (ATRA-sensitive), and HCT-116 (ATRA-
resistant) [30] were grown in Dulbecco’s modified Eagle medium with 100 µM non-essential
amino acids, RPMI 1640, and McCoy’s 5A medium, respectively. All media were
supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 55 IU/mL penicillin,
55 µg/mL streptomycin, and 1.5 µg/mL fungizone (Invitrogen). The cell lines were kept at
37°C in a humidified atmosphere of 5% CO2 and 95% air. All experiments were performed
on day 4–5 after seeding and all ATRA stimulations were performed in the dark. The cells
were left in 1.5% FBS or serum-free medium overnight to synchronize the cells and were
subsequently treated with 1 or 10 µM ATRA, 40 nM LTC4, 1 µM AP 100984, and/or 2 mM
sodium butyrate for the time points indicated. Inhibitors were added 30 min before ATRA
stimulation. For time courses, all cells were harvested at the same time.
Western blot
Except for siRNA experiments, whole cell lysates were used for Western blot analysis of
CysLT1R and CysLT2R. Cells were harvested in Tris lysis buffer on ice supplemented with
1% (v/v) Triton X-100 and protease inhibitors and homogenized 10 times with a Dounce
homogenizer and centrifuged at 200 × g for 10 min. The supernatant was centrifuged at 1000
× g for 5 min to remove cell debris. For Western blot experiments analyzing, RARα, and
RARβ, a Nuclear Extraction kit (Merck Millipore) was used according to the supplier’s
instruction and CysLT2R membrane fractions were prepared as in [18]. The
Coomassie/Bradford method (Pierce) was used to determine protein content, and equivalent
protein amounts for each sample were used. Gel electrophoresis and immunoblotting was
performed as described in [31] and the blots were scanned in a Molecular Imager ChemiDoc
XRS+ with Image Lab software (Biorad). Stripping of the membranes was performed
according to the supplier’s instructions (Re-blot Plus, Merck Millipore) and reprobed in the
same way.
qPCR analysis
Cells for RNA isolation were washed twice in PBS and immediately frozen at -80°C. The
cells were scraped in the lysis buffer provided in the RNeasy Plus Mini kit (Qiagen GmbH)
and homogenized 10 times with a 20-G needle. The RNA was isolated and purified according
to the supplier’s instructions. In short, genomic DNA was removed and RNA was bound to
RNeasy spin columns, washed, and dissolved in RNase-free water. cDNA synthesis was
performed using RevertAid H Minus M-MuLV reverse transcriptase and oligo(dT)18 primers
(Fermentas, Burlington, Canada). The mRNA expression levels of CysLT1R, CysLT2R, LTC4
synthase, mucin-2 (MUC-2), RARα, and the endogenous reference gene HPRT-1 were
quantified using MaximaTM
Probe qPCR Master Mix (2x) (Fermentas). The cDNA was
mixed with 0.9 µM TaqMan primers and master mix and amplified at 60°C in a Mx3005P
thermocycler (Stratagene). The following Taqman primer sets (Applied Biosystems) were
used: CYSLTR1, Hs00929113_m1; CYSLTR2, Hs00252658_s1; MUC2, Hs00159374_m1;
LTC4S, Hs00168529_m1; RARA, Hs00940446_m1; RARB, Hs00977140_m1; and HPRT-1,
6. Hs99999909_m1. The samples were analyzed and normalized against HPRT-1 using the
MxPro software (Stratagene).
siRNA experiments
Transient siRNA transfections of SW480 cells were carried out according to the
manufacturer’s instructions. Briefly, 3 days after seeding and at approximately 50%
confluence, cells were transfected for 4–6 h in Opti-MEM with reduced-serum without
antibiotics, with a mixture of Lipofectamine 2000, and 50–100 nM RARα, RARβ, or control
(non-targeting) siRNA. Human RARα (sc-29465), RARβ siRNA (sc-29466), and control
siRNA-A, -B, and -C (sc-37007, sc-44230, sc-44231 respectively) were from Santa Cruz
Biotechnology and ON-TARGETplus SMARTpool L-003437-00-0005, L-003438-00-005
and ON-TARGETplus Non-Targeting Pool D-001810-10-05, from Dharmacon. The cells
were allowed to rest for at least 24 h in complete medium, left in 1.5% FBS or serum-free
medium overnight, and stimulated on day 5 as described above.
Alkaline phosphatase activity
Alkaline phosphatase activity was measured using disodium p-nitrophenyl phosphate as the
substrate. Caco-2 cells were seeded in Petri dishes and incubated for 24 h at 37°C in complete
Dulbecco’s modified Eagle medium that was ultraviolet-treated to remove any traces of
endogenous retinoids. ATRA (1 µM) and/or AP 100984 (1 µM) were added and the cells
were incubated for a total of 72 h at 37°C. Every 24 h, the medium was renewed and ATRA
and/or AP 100984 were added as before. Sodium butyrate (2 mM) was used as a positive
control (data not shown). Five replicates per sample of scraped and lysed cells (PBS, 0.5%
Triton X-100) were added to a 96-well plate. The alkaline phosphatase activity was estimated
after incubation with disodium p-nitrophenyl phosphate for 30 min at 37°C by measuring the
absorbance at 405 nm due to formation of p-nitrophenol. The assay was performed as
previously described in [32]. The samples were normalized for equal protein content.
ELISA LTC4
SW480 cells were grown for 5 days in normal medium containing 10% serum after which the
medium was changed to 1.5% serum containing medium and treated with or without 1 µM
ATRA for 24 h. The media were then collected and separated by solid-phase extraction.
LTC4 from the samples were measured using the LTC4 ELSA kit from Cayman.
Thymidine incorporation assay
Five thousand SW480 cells per well were seeded and cultured for 2 days in flat-bottomed,
96-well plates. Cells were serum starved overnight and subsequently stimulated for 48 h with
1 µM ATRA in the presence or absence of 1 µM AP 100984 (CysLT2R inhibitor) or with
medium containing 10% serum as a positive control for proliferation. Cellular DNA synthesis
was assessed by adding 0.5 µCi 3
H-thymidine (GE Healthcare) during the final 18 h of
stimulation. The cells were washed once with PBS and incubated with 0.05% trypsin-EDTA
solution for 10 min at 37°C. Cells were harvested, collected on filter paper, and 3
H thymidine
incorporation was measured in a 1450 Microbeta Trilux liquid scintillation counter (Wallac,
Turku, Finland).
7. Caspase-3 activity
SW480 cells were cultured in 6-well plates for 4 days. Cells were incubated overnight in
medium containing 1.5% serum and subsequently stimulated for 48 h with 1 µM ATRA in
the presence or absence of 1 µM AP 100984. Taxol (100 nM) was used as a positive control
for apoptosis. The cells were lysed for 15 min on ice in 300 µL buffer containing 1% (v/v)
Triton X-100, 10 mM Tris–HCl (pH 7.4), 10 mM NaH2PO4/Na2HPO4 (pH 7.5), 10 mM
sodium pyrophosphate, and 130 mM NaCl. Samples (50 µL) were suspended in reaction
buffer (200 µL 20 mM HEPES, 2 mM dithiothreitol, and 10% glycerol) and added to Nunc
Polysorb 96-well plates where a caspase-3 fluorometric substrate, Ac-Asp-Glu-Val-Asp-
AMC (3 µL; Upstate), was subsequently added. The plates were incubated at 37°C for 1 h in
the dark, and the fluorescence of each well was measured at 390 nm excitation and 460 nm
emission wavelengths using a BMG plate reader (Offenburg, Germany). Triplicate samples
were analyzed and adjusted for equal protein content.
Luciferase reporter assay
A Renilla control reporter plasmid and a pGL3-Enhancer vector with a luciferase reporter
gene containing 1000 base pairs of the CYSLTR2 gene promoter (−1 to-1012) was used for
CysLT2R activity assays [32]. SW480 cells (5–10 × 104
per well) were seeded in 12-well
plates. Cells were transfected on day 3 with a mixture of the plasmids and Lipofectamine
2000 or LTX in Opti-MEM according to the supplier’s instructions. The final DNA amount
per well was 1 µg for the pGL3 plasmid and 50 ng for the Renilla control vector. When
siRNA was co-transfected, 50 nM per well was used. The transfection medium was changed
to complete RPMI 1640 with 10% FBS after 5–6 h and incubated for 24 h. The medium was
changed to serum-free or serum-low (1.5%) medium and cells were incubated overnight
before stimulation with 10 µM ATRA. After 48 h of ATRA stimulation, the experiments
were finished by rinsing the wells twice with PBS and adding passive lysis buffer from the
Dual-Luciferase Reporter Assay System from Promega (Madison, WI). The plates were
placed on an orbital shaker at a slow rate for 30 min and frozen (−20°C) until analysis. Firefly
and Renilla luminescence were measured on a MiniLumat LB 9506 (Berthold Technologies)
according to the protocol for the Dual-Luciferase Reporter Assay System and the ratio was
calculated.
Immunofluorescence
Cells were seeded on glass cover slips and grown for 3 days before being stimulated with 10
µM ATRA for 24 h in the absence of serum. The medium was removed and after several
washes with PBS the cells were fixed with 4% paraformaldehyde for 15 min and
subsequently permeabilized with 0.1% Triton X-100 for 5 min. Non-specific binding was
blocked with 3% goat serum in PBS for 45 min. Cells were incubated with a primary mucin-2
(MUC-2) antibody (Santa Cruz, diluted 1:50) in 1% goat serum/PBS for 1 h followed by
incubation with a secondary Alexa-488 antibody (Molecular Probes, diluted 1:500) for 1 h at
room temperature. After washing in PBS, the cover slips were mounted on glass slides with
fluorescent mounting medium. Confocal microscopy images were recorded using Zeiss LSM
700 (Carl Zeiss Microscopy GmbH, Jena, Germany).
8. Statistics
Data was analyzed using PRISM® software (GraphPad Software Inc., La Jolla, CA). One-
way ANOVA; unpaired one-sample t-test was performed when samples were compared to a
control set to 100% or 1. In all other cases, an unpaired t-test was performed. Values of P <
0.05 were considered statistically significant.
Results
ATRA treatment increases CysLT2R expression in colon cancer cells
ATRA is an established differentiation-inducing agent of epithelial cells [33] and we
previously found that CysLT2R signaling also induces differentiation of colon cancer cells
[18]. When either SW480 or Caco-2 colon cancer cells were stimulated with 1 µM ATRA,
CysLT2R mRNA was induced 3 h after treatment (Figure 1A and C). Protein levels of
CysLT2R also increased significantly, peaking at 3 h in SW480 cells and between 3–12 h in
Caco-2 cells (Figure 1B and D). Because CysLT2R has been suggested to have opposing
activities to those of CysLT1R, we next investigated the effect of ATRA on CysLT1R [18,19].
Unlike CysLT2R, which seems to play a role in differentiation, CysLT1R has mitogenic and
pro-survival effects [15,16]. High CysLT1R expression correlates with poor prognosis of
colorectal cancer patients [20]. We stimulated SW480 cells with 1 µM ATRA for 3–24 h, but
failed to observe an induction in CysLT1R expression, at either the mRNA or protein level
(Figure 1E and F).
Figure 1 CysLT2R expression in ATRA-treated colon cancer cell lines. Cells were
incubated for 3, 12, or 24 h in the absence or presence of 1 µM ATRA as indicated. (A and
C) qPCR for CysLT2R expression. Data are normalized to HPRT-1 in SW480 and Caco-2
cells. (B and D) Protein expression of CysLT2R normalized to β-actin in SW480 and Caco-2
cells as determined by Western blot. (E) qPCR for CysLT1R expression in SW480 cells. Data
are normalized to HPRT-1. (F) Protein expression of CysLT1R normalized to β-actin in
SW480 cells as determined by Western blot. Changes in CysLT2R expression relative to
basal levels in unstimulated cells are shown as mean ± standard error of the mean (SEM; *P
< 0.05, **P < 0.01; n.s. = not significant).
RARα knockdown decreases ATRA-induced CysLT2R mRNA and protein
expression
RARs are nuclear hormone receptors for ATRA, which upon ligand binding enable the
transcription of target genes [33]. Transfection of SW480 cells with siRNA against RARα,
but not RARβ decreased the induction of CysLT2R mRNA in response to ATRA stimulation
(Figure 2A). qPCR analysis showed that RARα siRNA downregulated RARα mRNA levels
to approximately 50% (Figure 2B). The mRNA expression of RARβ when treated with
RARβ siRNA was downregulated to the same extent (50%) but was less specific,
downregulating RARα mRNA to a similar level (data not shown). We used the nuclear
fraction for RARs (Figure 2C) and membrane fraction for CysLT2R (Figure 2D) protein
detection. The induction of CysLT2R protein in the membrane fraction by ATRA was also
abolished when siRNA against RARα was added (Figure 2D). The effect of siRNA treatment
on the respective protein levels was similar to that observed for the mRNA (i.e., no or little
induction after ATRA stimulation; Figure 2A-D).
9. Figure 2 Effect of RARα or RARβ inhibition on CysLT2R expression and promoter
activity. SW480 cells were transfected with control siRNA (non-target siRNA), RARα
siRNA, or/and RARβ siRNA, allowed to rest for 24 h, serum-starved overnight, and
subsequently stimulated with 10 µM ATRA. (A and B) qPCR for CysLT2R and RARα
expression. Data are normalized to HPRT-1 with and without ATRA stimulation for 3 h. (C)
Western blots without and with ATRA stimulation for 3 h. (D) Western blot analyzes of
CysLT2R protein expression in membrane fractions from SW480 cells stimulated or not with
ATRA for 3 h normalized to unstimulated control. (E) CysLT2R luciferase promoter activity
in cells stimulated with or without ATRA for 48 h. Data are normalized to unstimulated
controls. (F) CysLT2R luciferase promoter activity in siRNA-treated cells stimulated with or
without ATRA for 48 h. Data are normalized to unstimulated control. Values are shown as
mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
To study CysLT2R promoter activity, SW480 cells were transiently transfected with a
luciferase reporter gene vector and stimulated with ATRA. A dose response was observed
with increasing ATRA concentration (0.1, 1.0, and 10 µM; Figure 2E). Stimulation with 10
µM ATRA was chosen for the inhibition studies in which cells were treated with siRNAs
targeting the RARs. Neither RARα siRNA nor RARβ siRNA induced any significant change
in basal CysLT2R promoter activity (Figure 2F). However, in contrast to the activation seen
for the regulation of the endogenous CysLT2R gene (Figure 2D), siRNA knockdown of
RARα or RARβ or a combination of the two did not affect the ATRA-induced activation of
the transfected partial/putative CysLT2R promoter (Figure 2F).
ATRA does not affect the proliferation of SW480 colon cancer cells
The effects of ATRA on tumor suppression cannot be entirely attributed to its role in
differentiation, as ATRA has also been reported to inhibit growth of some colon cancer cell
lines [27,34]. To determine whether ATRA has such an activity in our system, we pre-
incubated SW480 cells with or without 1 µM CysLT2R antagonist AP 100984 and stimulated
the cells with 1 µM ATRA or 40 nM LTC4 for 48 h. DNA synthesis was measured as the
amount of 3
H-thymidine incorporated during the last 18 h of stimulation. Neither ATRA nor
LTC4, alone or in combination, induced any changes in DNA synthesis compared to
unstimulated cells (Figure 3A). Complete medium with 10% FBS was used as a positive
control for proliferation and induced a 2-fold increase in 3
H-thymidine incorporation. These
data showed that neither ATRA nordoes the CysLT2R inhibitor AP 100984 have any effect
on SW480 cell growth.
Figure 3 Effect of ATRA on cell growth, apoptosis, LTC4S and LTC4 expression. SW480
cells were treated with the CysLT2R inhibitor AP 100984 (AP) and/or 40 nM LTC4 and were
or were not stimulated with 1 µM ATRA. (A) 3
H-thymidine incorporation measured after 72
h of ATRA treatment, normalized to unstimulated control. (B) Caspase-3 activity after 48 h
of ATRA treatment normalized to unstimulated control. (C) qPCR for LTC4S expression
after 3–24 h of ATRA stimulation. Data are normalized to HPRT-1. (D) Release of LTC4 into
the media form SW480 cells after 24 h incubation in the absence or presence of ATRA.
Values are shown as mean ± SEM (*P < 0.05, **P < 0.01).
10. Effects of ATRA on apoptosis, LTC4S mRNA and LTC4 expression in SW480
cells
In some cell types, ATRA induces apoptosis through the caspase-3 pathway [35]. We
therefore investigated whether ATRA could induce apoptosis in these colon cancer cells. The
cells were incubated with or without 1 µM CysLT2R inhibitor AP 100984 and stimulated
with 1 µM ATRA for 48 h. Under these conditions, we were unable to observe apoptosis in
SW480 cells as measured by caspase-3 activity (Figure 3B). Taxol was used as a positive
control for apoptosis and induced a significant (50%) increase in caspase-3 activity. Neither
AP 100984 alone or in combination with ATRA had any effect on caspase-3 activity,
indicating that AP 100984 had no intrinsic apoptotic effect.
We next investigated whether ATRA could increase LTC4S mRNA expression. Cells were
stimulated with ATRA for 3, 12 or 24 h and the LTC4S mRNA level was determined with
qPCR. We observed a 4-fold increase of LTC4S mRNA in cells treated with ATRA for 12 h
compared to control cells (Figure 3C). The induction of LTC4S can enhance LTC4 production
and in turn induce CysLT2R activation, thus creating a positive feedback loop that promotes
differentiation. Therefore, we next examined the endogenous synthesis and release of LTC4
in SW480 cells, we found a basal release of 140 pg/ml LTC4 and a possible enhanced release
by ATRA to 190 pg/ml LTC4 in SW480 cells (Figure 3D).
ATRA does not induce CysLT2R expression in ATRA-resistant HCT-116 cells
The colon cancer cell line HCT-116 is ATRA-resistant [34]. We confirmed this with qPCR,
finding that stimulation of HCT-116 cells with 1 µM ATRA failed to induce mRNA
expression of CysLT2R at any of the time points observed (Figure 4A). Likewise, Western
blots of lysates harvested from cells treated with 1 µM ATRA for 3, 12, and 24 h showed
there was no effect on CysLT2R protein expression (Figure 4B). In case the effect on the
protein level was delayed, we also tested after 48 h of stimulation, but no significant change
from the unstimulated cells was observed.
Figure 4 ATRA does not affect CysLT2R in HCT-116 cells. RAR-mutated HCT-116 colon
cancer cells were incubated for 3, 12, or 24 h in the presence or absence of 1 µM ATRA. (A)
qPCR for CysLT2R expression in HCT-116 cells. Data are normalized to HPRT-1. (B)
Protein expression of CysLT2R normalized to β-actin in HCT-116 cells as determined by
Western blot. Data show changes in expression relative to basal levels in unstimulated cells.
(n.s. = not significant).
The CysLT2R antagonist AP 100984 reduces ATRA-induced MUC-2
expression and alkaline phosphatase activity
Mucins are secreted by colonocytes to form a mucus barrier to protect the intestinal
epithelium [36]. MUC-2 is down-regulated in many colorectal cancers and is associated with
the differentiated state of colonic epithelia [37]. We analyzed the expression of MUC-2
mRNA in SW480 cells and found that treatment with 1 µM ATRA increased MUC-2 mRNA
expression 2-fold after 3 h of stimulation (Figure 5A). When cells were pretreated with 1 µM
AP 100984, the ATRA-induced MUC-2 up-regulation was decreased. AP 100984 itself had
no effect on MUC-2 mRNA expression. Similarly, when cells were treated with RARα
siRNA, ATRA-induced MUC-2 expression was decreased by approximately 50% (Figure
11. 5B). Thus, ATRA-enhanced MUC-2 expression in SW480 colon cancer cells is at least partly
mediated through CysLT2R and RARα signaling. Furthermore, we also found by
immunofluorescence that the MUC-2 protein expression was increased after treatment with
ATRA for 24 h (Figure 5C).
Figure 5 Effect of ATRA on the differentiation markers MUC-2 and alkaline
phosphatase activity. SW480 cells were either 1) treated with 1 µM of the CysLT2R
inhibitor AP 100984 (AP) and were or were not stimulated with 1 µM ATRA or 2) treated
with RAR siRNA and stimulated with 10 µM ATRA. (A and B) qPCR for MUC-2. Data are
normalized to HPRT-1 and changes in MUC-2 expression are relative to basal levels in
untreated cells. (C) Confocal immunofluorescence microscopy showing ATRA-induced
expression of Mucin-2 in SW480 colon cancer cells. After stimulation with 10 µM ATRA for
24 h the cells were fixed, permeabilized and stained with a Mucin-2 antibody. Left panels
show Mucin-2 (MUC-2) staining, middle panels nuclear staining with DAPI and right panels
merged, the graphs were taken with 40x objective. (D) Alkaline phosphatase activity in Caco-
2 cells. Bars show % of ATRA-induces alkaline phosphatase activity and values are shown as
mean ± SEM (*P < 0.05, **P < 0.01).
Alkaline phosphatase is one of the brush border enzymes expressed in the differentiated
epithelial cells of the intestines and alkaline phosphatase activity is often used as a
differentiation marker [38]. In accordance with others’ results from previous studies, we
found that ATRA is able to significantly induce alkaline phosphatase activity in Caco-2 cells,
as determined by the formation of para-nitrophenol (Figure 5D) [39]. Sodium butyrate was
included as a positive control for alkaline phosphatase activity, and increased the activity
approximately 2-fold compared to unstimulated cells (data not shown) [40]. Interestingly,
ATRA-induced alkaline phosphatase activity was significantly reduced upon pretreatment for
30 min with 1 µM CysLT2R inhibitor AP 100984. Addition of the inhibitor alone did not
affect basal alkaline phosphatase activity, suggesting that ATRA’s induction of alkaline
phosphatase activity is partly mediated through CysLT2R in Caco-2 cells. Together, the
MUC-2 expression and alkaline phosphatase activity studies shows that ATRA’s induction of
differentiation is at least partially dependent on CysLT2R signaling.
Discussion
ATRA is well known to induce differentiation of epithelial cells and we have also shown that
CysLT2R induces differentiation of epithelial cells [23,32]. We found putative RAREs within
the promoter region of the transcription start of the CYSLTR2 gene [32]. Based on this
finding, we hypothesized that ATRA could induce CysLT2R expression. We show here that
ATRA can indeed induce both mRNA and protein expression of CysLT2R in two different
colon cancer cell lines. Knock-down of RARα with siRNA decreases ATRA-induced
CysLT2R expression in SW480 cells. In accordance with this finding, ATRA was unable to
induce CysLT2R mRNA or protein expression in HCT-116 colon cancer cells, which lack
functional RARs. Neither mutations in these possible response elements nor truncation of the
inserted region changed the cell response to ATRA stimulation (see Additional file 1: Figure
S1). Furthermore, a high concentration of ATRA is required to observe any cellular response.
Together, these findings might suggest that ATRA’s induction of CysLT2R is mediated
indirectly or that the intracellular RAR levels are low. This is in agreement with findings that
the relative expression of RARα is higher than RARβ in human intestine and the overall
12. expression of RARs (especially RARβ2) is lower in tumors than normal tissue due to
epigenetic modifications [28].
Previous studies showed that CysLT2R can be up-regulated by the cytokines interferon γ
(IFNγ) and interleukin-4 in monocytes, T cells, and B cells and by interleukin-13 in
monocytes [41,42]. Further, consistent with its role in inflammatory responses. Bai et al. [43]
have shown that ATRA can down-regulate the colon inflammatory response as measured by
tumor necrosis factor alpha (TNFα) levels, in patients with IBD in vitro and in a murine
colitis model in vivo. We previously found that TNFα also down-regulates CysLT2R while
up-regulating CysLT1R in colon cancer cells [44], an observation that also highlights the
importance of maintaining receptor balance in epithelial cells [18].
ATRA has previously been shown to induce mRNA expression, protein expression, and
promoter activity of LTC4S in rat basophilic leukemia cells. LTD4 is a ligand for CysLT1R
that up-regulates both LTC4S and CysLT2R in intestinal epithelial and colon cancer cells
[44]. These activities are associated with differentiation, but the underlying signaling
mechanism remained unclear [29]. We show for the first time that ATRA is capable of up-
regulating both LTC4S mRNA in epithelial cells. LTC4S is responsible for the production of
the cysteinyl leukotriene LTC4. Furthermore, ATRA by inducing both CysLT2R and possibly
its ligand, activates a signaling pathway that has beneficial effects on colon epithelial cell
differentiation.
MUC-2 and brush border enzymes are typical markers of differentiated colonocytes [45]. We
have previously shown that LTC4 stimulation of CysLT2R induces differentiation in Caco-2
colon cancer cells, as measured by increased MUC-2 mRNA expression and increased
activity of the brush border enzymes alkaline phosphatase and aminopeptidase N [18]. ATRA
has also been shown to induce MUC-2 protein via PKCα and CREB in airway human
tracheobronchial epithelial cells [46]. Furthermore, rats on a retinoid-deficient diet have
decreased MUC-2 mRNA expression in the jejunum, ileum, and colon [47]. These studies
indicate that ATRA and CysLT2R have similar functions in epithelial differentiation, as
evidenced by MUC-2 expression. In the current study, we show that ATRA’s ability to
induce MUC-2 expression in SW480 colon cancer cells might also involve CysLT2R
signaling, as the effect can be reduced by either a CysLT2R inhibitor or by RARα siRNA
alone or a combination of RARα and RARβ siRNA. Moreover, we found that ATRA-induced
alkaline phosphatase activity could be reduced by pretreatment with the same CysLT2R
inhibitor. Our findings indicate that CysLT2R signaling, likely in concert with other
pathways, contributes to ATRA’s differentiation-inducing activity.
In addition to being a powerful differentiation-inducing agent, ATRA can inhibit growth in
some colon cancer cell lines [48]. Therefore, we investigated whether ATRA primarily
affects differentiation in SW480 cells, or also inhibits growth. In HT-29 cells ATRA-induced
growth inhibition is mediated by RARα [49], whereas, in Caco-2 cells it is mediated by
RARβ [50]. However, other studies have reported that ATRA has no effect on growth
inhibition in HT-29 cells [27]. In certain contexts, ATRA also has the ability to mediate
apoptosis [35]. In our study, we were unable to observe any effects of ATRA on growth
inhibition or apoptosis in SW480 cells, suggesting that ATRA’s main activity in these cells is
to induce cell differentiation.
Although the CYSLTR2 gene has been mapped to chromosome 13q14, a region linked to
atopic asthma [9], it remains unclear how the gene is regulated. When studying the promoter
13. region of CysLT2R, we found a binding site for IRF-7 that showed reporter gene activity
upon IFNα stimulation [32]. This finding encouraged us to further investigate whether other
regulatory elements in the region were present. This analysis led us to identify, for the first
time, putative RARE elements in the promoter region of CysLT2R. Stimulation with ATRA
increased CysLT2R promoter activity in a reporter gene assay, but neither mutations nor
truncations in the RARE elements decreased the activity. In the present study, we found a
discrepancy between the regulation of the endogenous CysLT2R gene activity and the
regulation of a transfected partial/putative promoter of the same gene. At present we do not
know the reason for this discrepancy, but a couple of explanations can be considered. First,
the transfected CysLT2R promoter is expressed at a level that in comparison with the
endogenous promoter is significantly higher and therefore relatively low level of RARs do
not have the same ability to regulate its activity as they have when only the endogenous
promoter for CysLT2R is present. Secondly, another possibility is that our transfected
putative CysLT2R promoter is lacking crucial bindings sites for some enhancer/cofactor that
is vital for its proper regulation. Thirdly, in addition to direct ligand-dependent transcription
of genes, there can be indirect effects such transactivation of other transcription factors
independently of any RAR and also non-genomic mechanisms of action of ATRA [51].
Finally, our data might suggest that the effect of ATRA on CysLT2R promoter activity is
indirect and does not involve these putative RARs. Clearly, this issue requires extensive
future work before it can be resolved.
Most of the studies investigating the role of RAREs in promoters have focused on proteins
involved in retinoid transport or catabolism [52,53] or developmental regulation, where
ATRA is considered a ‘master switch’ for differentiation. For example, ATRA induces hoxb1
expression, a gene responsible for gut development in mouse embryos [54]. Other ATRA-
induced transcription factors or cofactors include STAT-1, Oct3/4, Hoxa1, and Hoxb4
[53,55]. Retinoids also have the ability to repress genes. In a mouse epidermal cell line,
retinoids block tumor promotion by inhibiting AP-1 [56]. Interestingly, we previously
observed that signaling through CysLT1R induces activation of the AP-1 pathway in
intestinal epithelial cells, leading to increased proliferation [57]. Here we show that
expression of CysLT1R is unaffected by ATRA treatment. High CysLT1R expression in
cancer patients is not restricted to colorectal cancer cells; it has also been observed in
transitional cell carcinoma of the bladder [58], neuroblastoma [59], astrocytoma [60], and in
classical Hodgkin’s lymphoma [61]. ATRA’s mechanism of action on cysteinyl leukotriene
receptors may also highlight a signaling pathway that contributes to other cancer types.
We show for the first time that in human colon cancer cells, the differentiation agent ATRA
acts in part by inducing both LTC4S, an enzyme responsible for the generation of CysLTs,
and CysLT2R, a receptor for these ligands. Furthermore, we report that this effect is very
likely mediated through RARα or a combination of RARα and RARβ and presumably acts
through a mediator that can regulate CysLT2R. ATRA-induced differentiation can partially be
reduced by a CysLT2R inhibitor, implying that CysLT2R contributes to this differentiation.
Finally, ATRA does not induce expression of the pro-mitogenic CysLT1R.
Conclusions
We suggest here a mechanism by which ATRA induces differentiation, in part by increasing
CysLT2R expression. Our data shed new light on how ATRA exerts its effects on colorectal
cancer cell differentiation and demonstrates that retinoids are able to delicately regulate the
balance between different elements in the cysteinyl leukotriene pathway. Further work is
14. necessary to elucidate the interplay between retinoids and eicosanoids, but the knowledge
gained from such studies could yield new insights for designing colon cancer therapy
regimens.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AB, GJ and AS conceived and designed the study. AB, GJ, CA, TS and CM performed the
experiments and analyzed the data. AB, GJ, and AS drafted the paper. All authors read and
approved the final manuscript.
Acknowledgements
We thank Jilly F. Evans at Amira Pharmaceuticals for providing the CysLT2 inhibitor AP
100984. This study was supported by grants to A.S. from the Swedish Cancer Foundation, the
Swedish Medical Research Council, the Foundations at Malmö University Hospital, the
Gunnar Nilsson Foundation, and the Österlund Foundation, and to A.B. and C.M. from the
Royal Physiographic Society in Lund.
References
1. Eaden J: Review article: colorectal carcinoma and inflammatory bowel disease.
Aliment Pharmacol Ther 2004, 20(Suppl 4):24–30.
2. Ekbom A, Helmick C, Zack M, Adami HO: Ulcerative colitis and colorectal cancer. A
population-based study. N Engl J Med 1990, 323(18):1228–1233.
3. Nakamura M, Shimizu T: Leukotriene receptors. Chem Rev 2011, 111(10):6231–6298.
4. Singh RK, Gupta S, Dastidar S, Ray A: Cysteinyl leukotrienes and their receptors:
molecular and functional characteristics. Pharmacology 2010, 85(6):336–349.
5. Sharon P, Stenson WF: Enhanced synthesis of leukotriene B4 by colonic mucosa in
inflammatory bowel disease. Gastroenterology 1984, 86(3):453–460.
6. Kim JH, Tagari P, Griffiths AM, Ford-Hutchinson A, Smith C, Sherman PM: Levels of
peptidoleukotriene E4 are elevated in active Crohn's disease. J Pediatr Gastroenterol
Nutr 1995, 20(4):403–407.
7. Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K: 5-Lipoxygenase inhibitors for the
treatment of inflammatory bowel disease. Agents Actions 1992:37–46.
8. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, Coulombe N, Abramovitz
M, Figueroa DJ, Zeng Z, et al: Characterization of the human cysteinyl leukotriene
CysLT1 receptor. Nature 1999, 399(6738):789–793.
15. 9. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R, Bellefeuille
JN, Abramovitz M, Cheng R, et al: Characterization of the human cysteinyl leukotriene 2
receptor. J Biol Chem 2000, 275(39):30531–30536.
10. Capra V, Ravasi S, Accomazzo MR, Citro S, Grimoldi M, Abbracchio MP, Rovati GE:
CysLT1 receptor is a target for extracellular nucleotide-induced heterologous
desensitization: a possible feedback mechanism in inflammation. J Cell Sci 2005, 118(Pt
23):5625–5636.
11. Nielsen CK, Massoumi R, Sonnerlind M, Sjolander A: Leukotriene D4 activates
distinct G-proteins in intestinal epithelial cells to regulate stress fibre formation and to
generate intracellular Ca2+ mobilisation and ERK1/2 activation. Exp Cell Res 2005,
302(1):31–39.
12. Adolfsson JL, Ohd JF, Sjolander A: Leukotriene D4-induced activation and
translocation of the G-protein alpha i3-subunit in human epithelial cells. Biochem
Biophys Res Commun 1996, 226(2):413–419.
13. Paruchuri S, Hallberg B, Juhas M, Larsson C, Sjolander A: Leukotriene D(4) activates
MAPK through a Ras-independent but PKCepsilon-dependent pathway in intestinal
epithelial cells. J Cell Sci 2002, 115(Pt 9):1883–1893.
14. Thodeti CK, Nielsen CK, Paruchuri S, Larsson C, Sjolander A: The epsilon isoform of
protein kinase C is involved in regulation of the LTD(4)-induced calcium signal in
human intestinal epithelial cells. Exp Cell Res 2001, 262(2):95–103.
15. Paruchuri S, Sjolander A: Leukotriene D4 mediates survival and proliferation via
separate but parallel pathways in the human intestinal epithelial cell line Int 407. J Biol
Chem 2003, 278(46):45577–45585.
16. Paruchuri S, Broom O, Dib K, Sjolander A: The pro-inflammatory mediator
leukotriene D4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of
intestinal epithelial cells. J Biol Chem 2005, 280(14):13538–13544.
17. Ohd JF, Wikstrom K, Sjolander A: Leukotrienes induce cell-survival signaling in
intestinal epithelial cells. Gastroenterology 2000, 119(4):1007–1018.
18. Magnusson C, Ehrnstrom R, Olsen J, Sjolander A: An increased expression of cysteinyl
leukotriene 2 receptor in colorectal adenocarcinomas correlates with high
differentiation. Cancer Res 2007, 67(19):9190–9198.
19. Jiang Y, Borrelli LA, Kanaoka Y, Bacskai BJ, Boyce JA: CysLT2 receptors interact
with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic
responses of mast cells. Blood 2007, 110(9):3263–3270.
20. Ohd JF, Nielsen CK, Campbell J, Landberg G, Lofberg H, Sjolander A: Expression of
the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in
colorectal adenocarcinomas. Gastroenterology 2003, 124(1):57–70.
16. 21. Niederreither K, Dolle P: Retinoic acid in development: towards an integrated view.
Nat Rev Genet 2008, 9(7):541–553.
22. Mongan NP, Gudas LJ: Diverse actions of retinoid receptors in cancer prevention and
treatment. Differentiation 2007, 75(9):853–870.
23. Clarke N, Germain P, Altucci L, Gronemeyer H: Retinoids: potential in cancer
prevention and therapy. Expert Rev Mol Med 2004, 6(25):1–23.
24. Newberne PM, Bueche D, Riengropitak S, Schrager TF: The influence of dietary levels
of vitamin A and fat on colon cancer. Nutr Cancer 1990, 13(4):235–242.
25. Zheng Y, Kramer PM, Olson G, Lubet RA, Steele VE, Kelloff GJ, Pereira MA:
Prevention by retinoids of azoxymethane-induced tumors and aberrant crypt foci and
their modulation of cell proliferation in the colon of rats. Carcinogenesis 1997,
18(11):2119–2125.
26. Paulsen JE, Lutzow-Holm C: In vivo growth inhibition of human colon carcinoma
cells (HT-29) by all-trans-retinoic acid, difluoromethylornithine, and colon mitosis
inhibitor, individually and in combination. Anticancer Res 2000, 20(5B):3485–3489.
27. Lee MO, Han SY, Jiang S, Park JH, Kim SJ: Differential effects of retinoic acid on
growth and apoptosis in human colon cancer cell lines associated with the induction of
retinoic acid receptor beta. Biochem Pharmacol 2000, 59(5):485–496.
28. Modica S, Gofflot F, Murzilli S, D'Orazio A, Salvatore L, Pellegrini F, Nicolucci A,
Tognoni G, Copetti M, Valanzano R, et al: The intestinal nuclear receptor signature with
epithelial localization patterns and expression modulation in tumors. Gastroenterology
2010, 138(2):636–648. 648 e631-612.
29. Abe M, Shibata K, Urata H, Sakata N, Katsuragi T: Induction of leukotriene C4
synthase after the differentiation of rat basophilic leukemia cells with retinoic acid and
a low dose of actinomycin D and its suppression with methylprednisolone. J Cell Physiol
2003, 196(1):154–164.
30. Park EY, Wilder ET, Lane MA: Retinol inhibits the invasion of retinoic acid-resistant
colon cancer cells in vitro and decreases matrix metalloproteinase mRNA, protein, and
activity levels. Nutr Cancer 2007, 57(1):66–77.
31. Nielsen CK, Campbell JI, Ohd JF, Morgelin M, Riesbeck K, Landberg G, Sjolander A: A
novel localization of the G-protein-coupled CysLT1 receptor in the nucleus of colorectal
adenocarcinoma cells. Cancer Res 2005, 65(3):732–742.
32. Magnusson C, Bengtsson AM, Liu M, Liu J, Ceder Y, Ehrnstrom R, Sjolander A:
Regulation of cysteinyl leukotriene receptor 2 expression–a potential anti-tumor
mechanism. PLoS One 2011, 6(12):e29060.
33. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM: Retinoids in
chemoprevention and differentiation therapy. Carcinogenesis 2000, 21(7):1271–1279.
17. 34. Park EY, Dillard A, Williams EA, Wilder ET, Pepper MR, Lane MA: Retinol inhibits
the growth of all-trans-retinoic acid-sensitive and all-trans-retinoic acid-resistant colon
cancer cells through a retinoic acid receptor-independent mechanism. Cancer Res 2005,
65(21):9923–9933.
35. Gumireddy K, Sutton LN, Phillips PC, Reddy CD: All-trans-retinoic acid-induced
apoptosis in human medulloblastoma: activation of caspase-3/poly(ADP-ribose)
polymerase 1 pathway. Clin Cancer Res 2003, 9(11):4052–4059.
36. Sheng YH, Hasnain SZ, Florin TH, McGuckin MA: Mucins in inflammatory bowel
diseases and colorectal cancer. J Gastroenterol Hepatol 2012, 27(1):28–38.
37. Byrd JC, Bresalier RS: Mucins and mucin binding proteins in colorectal cancer.
Cancer Metastasis Rev 2004, 23(1–2):77–99.
38. Olsen L, Bressendorff S, Troelsen JT, Olsen J: Differentiation-dependent activation of
the human intestinal alkaline phosphatase promoter by HNF-4 in intestinal cells. Am J
Physiol Gastrointest Liver Physiol 2005, 289(2):G220–226.
39. Bartolini G, Ammar K, Mantovani B, Scanabissi F, Ferreri AM, Rocchi P, Orlandi M:
Retinoids and cancer: antitumor effect of ATRA and of a new derivative of retinoic
acid, IIF, on colon carcinoma cell lines CaCo-2 and HT-29. Anticancer Res 2004,
24(3a):1779–1783.
40. Wang Q, Wang X, Hernandez A, Kim S, Evers BM: Inhibition of the
phosphatidylinositol 3-kinase pathway contributes to HT29 and Caco-2 intestinal cell
differentiation. Gastroenterology 2001, 120(6):1381–1392.
41. Early SB, Barekzi E, Negri J, Hise K, Borish L, Steinke JW: Concordant Modulation of
Cysteinyl Leukotriene Receptor Expression by IL-4 and IFN-{gamma} on Peripheral
Immune Cells. Am J Respir Cell Mol Biol 2007, 36(6):715–720.
42. Shirasaki H, Seki N, Fujita M, Kikuchi M, Kanaizumi E, Watanabe K, Himi T: Agonist-
and T(H)2 cytokine-induced up-regulation of cysteinyl leukotriene receptor messenger
RNA in human monocytes. Ann Allergy Asthma Immunol 2007, 99(4):340–347.
43. Bai A, Lu N, Guo Y, Liu Z, Chen J, Peng Z: All-trans retinoic acid down-regulates
inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and
murine colitis. J Leukoc Biol 2009, 86(4):959–969.
44. Yudina Y, Parhamifar L, Bengtsson AM, Juhas M, Sjolander A: Regulation of the
eicosanoid pathway by tumour necrosis factor alpha and leukotriene D4 in intestinal
epithelial cells. Prostaglandins Leukot Essent Fatty Acids 2008, 79(6):223–231.
45. Smith AC, Podolsky DK: Colonic mucin glycoproteins in health and disease. Clin
Gastroenterol 1986, 15(4):815–837.
46. Kim SW, Hong JS, Ryu SH, Chung WC, Yoon JH, Koo JS: Regulation of mucin gene
expression by CREB via a nonclassical retinoic acid signaling pathway. Mol Cell Biol
2007, 27(19):6933–6947.
18. 47. Amit-Romach E, Uni Z, Cheled S, Berkovich Z, Reifen R: Bacterial population and
innate immunity-related genes in rat gastrointestinal tract are altered by vitamin A-
deficient diet. J Nutr Biochem 2009, 20(1):70–77.
48. Nicke B, Riecken EO, Rosewicz S: Induction of retinoic acid receptor beta mediates
growth inhibition in retinoid resistant human colon carcinoma cells. Gut 1999, 45(1):51–
57.
49. Nicke B, Kaiser A, Wiedenmann B, Riecken EO, Rosewicz S: Retinoic acid receptor
alpha mediates growth inhibition by retinoids in human colon carcinoma HT29 cells.
Biochem Biophys Res Commun 1999, 261(3):572–577.
50. McCormack SA, Viar MJ, Tague L, Johnson LR: Altered distribution of the nuclear
receptor RAR beta accompanies proliferation and differentiation changes caused by
retinoic acid in Caco-2 cells. In Vitro Cell Dev Biol Anim 1996, 32(1):53–61.
51. Blomhoff R, Blomhoff HK: Overview of retinoid metabolism and function. J
Neurobiol 2006, 66(7):606–630.
52. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N: Opposing effects of retinoic acid on
cell growth result from alternate activation of two different nuclear receptors. Cell 2007,
129(4):723–733.
53. Freemantle SJ, Spinella MJ, Dmitrovsky E: Retinoids in cancer therapy and
chemoprevention: promise meets resistance. Oncogene 2003, 22(47):7305–7315.
54. Ross SA, McCaffery PJ, Drager UC, De Luca LM: Retinoids in embryonal
development. Physiol Rev 2000, 80(3):1021–1054.
55. McCaffery P, Drager UC: Regulation of retinoic acid signaling in the embryonic
nervous system: a master differentiation factor. Cytokine Growth Factor Rev 2000,
11(3):233–249.
56. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH: Blocking of tumor
promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse
epidermal cells. Proc Natl Acad Sci USA 1994, 91(2):609–613.
57. Bengtsson AM, Massoumi R, Sjolander A: Leukotriene D(4) induces AP-1 but not
NFkappaB signaling in intestinal epithelial cells. Prostaglandins Other Lipid Mediat 2007,
85(3-4):100–106.
58. Matsuyama M, Funao K, Hayama T, Tanaka T, Kawahito Y, Sano H, Takemoto Y,
Nakatani T, Yoshimura R: Relationship Between Cysteinyl-Leukotriene-1 Receptor and
Human Transitional Cell Carcinoma in Bladder. Urology 2009, 73(4):916–921.
59. Sveinbjornsson B, Rasmuson A, Baryawno N, Wan M, Pettersen I, Ponthan F, Orrego A,
Haeggstrom JZ, Johnsen JI, Kogner P: Expression of enzymes and receptors of the
leukotriene pathway in human neuroblastoma promotes tumor survival and provides a
target for therapy. FASEB J 2008, 22(10):3525–3536.
19. 60. Zhang WP, Hu H, Zhang L, Ding W, Yao HT, Chen KD, Sheng WW, Chen Z, Wei EQ:
Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and
brain tumors. Neurosci Lett 2004, 363(3):247–251.
61. Schain F, Tryselius Y, Sjoberg J, Porwit A, Backman L, Malec M, Xu D, Vockerodt M,
Baumforth KR, Wei W, et al: Evidence for a pathophysiological role of cysteinyl
leukotrienes in classical Hodgkin lymphoma. Int J Cancer 2008, 123(10):2285–2293.
Additional file
Additional_file_1 as PDF
Aditional file 1: Figure S1 CysLT2R luciferase activity in SW480 cells transfected with a
vector containing mutated putative RARE sites or truncations.